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CHAPTER 1
Overactive bladder syndrome (OAB) is a symptom complex characterized by urinary urgency, 
usually accompanied by increased frequency and nocturia, with or without urgency urinary 
incontinence, in the absence of a causative infection or pathological conditions. [1] OAB is 
very common and challenging to treat. OAB symptoms have a significant negative impact on 
quality of life of patients suffering from it, and incur high costs to healthcare services and to 
society. [2-4] In the past decades several treatment modalities for OAB have been developed 
and fundamental and clinical research is still ongoing in order to have more control over this 
symptom syndrome.
This thesis comprises items of clinical practice of OAB, the prevalence of OAB and the existing 
and experimental surgical treatment of OAB. The prevalence of OAB varies with age and sex. 
[2] Lower urinary tract symptoms (LUTS) is a collection of symptoms that concern the lower 
urinary tract in the storage phase, the micturition phase and the post-micturition phase. Part 
of these symptoms compose the OAB syndrome, i.e. urgency, frequency, nocturia and urgency 
incontinence. Knowledge of the prevalence of LUTS/OAB and the accompanying burden in 
different age groups and sex is important for establishing what can be considered as ‘normal’ 
in the general population. This is particularly important in the context of therapeutic studies. 
When the “physiologic prevalence” of symptoms and the accompanying bother is known, 
a better estimation of the therapy effect can be made. The prevalence and experienced 
burden of LUTS/OAB among young otherwise healthy nulligravid women has not yet 
been studied extensively. We studied this group of healthy women, which resulted in the 
publication that is listed in Chapter 2. In this study a high prevalence of LUTS was found, but it 
had low accompanying bother. LUTS was found in 94.3% of these women, urgency in 14.5% 
and urinary urgency incontinence in 3.8%. With respect to frequency, 9.5% of these females 
voided more than 9 times a day, whereas nocturia once a night was reported by 18.2 % of the 
women. In all symptoms there was a positive correlation between the increasing frequency 
and the experienced bother. The highest accompanying bother was found for urgency. 
Since these were all presumably healthy women, with low bother scores for the experienced 
symptoms, who did not seek or who were not intended to seek medical attention, the rather 
high percentages raise the question whether these ‘LUTS’ should be considered as normal or 
physiologic. 
Nowadays patients are typically first treated with conservative measures, like behavioral therapy 
and pelvic floor physiotherapy. If unsuccessful, treatment is mostly followed by a trial of oral 
therapy like antimuscarinics or β3 agonists. Minimal invasive treatment like neuromodulation 
by ways of percutaneous tibial nerve stimulation (PTNS) and sacral nerve stimulation (SNS) 
can be offered next, as well as botulinum toxin type A (BTA) injections. Last resort major 
surgical treatment like ileocystoplasty or ileal conduits may be offered only after the failure of 
conservative therapy or minimal invasive surgery. [5, 6] 
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General Introduction and outline of this thesis
Conservative treatment consists of patient education, lifestyle interventions such as caffeine 
reduction and fluid reduction, behavioral treatment, and physiotherapy involving pelvic-floor 
muscle training with or without biofeedback. Almost always these treatments will be offered 
in a certain combination. Behavioral therapy and physiotherapy are associated with a broad 
variation in rates of success ranging from 33% to 51%. [7-10] There is a wide variety in the 
extent to which individual therapists motivate, supervise, and monitor these interventions. 
Nevertheless, it is recognized that these are important components that affect the treatment 
outcome. [11] 
Oral therapy by means of antimuscarinics and β3 agonists in the management of overactive 
bladder syndrome is well established. [12-14] Antimuscarinics have been used for the lower 
urinary tract since the introduction of oxybutynin in 1975. There are five subtypes of muscarinic 
receptors on different organs throughout the body; M3 and M2 are the receptors responsible 
for detrusor contraction. [15] The antimuscarinic class of medications are competitive with 
acetylcholine for the muscarinic receptors inhibiting parasympathetic stimulation and 
reducing detrusor contraction. [16] A significant reduction in the bothersome symptoms of 
urgency, frequency and urinary urgency incontinence is seen with antimuscarinic use. [17-19] 
Nowadays several antimuscarinic drugs are available for example oxybutynin, tolterodine, 
solifenacin, darifenacin, and fesoterodine. Despite good efficacy, more than 50% of patients 
stop using antimuscarinic drugs within the first 3 months, because of adverse effects like a dry 
mouth or constipation. [5, 20] 
In the past medical management of OAB symptoms have focused primarily on inhibiting 
muscarinic mediated bladder contraction, however β3 adrenoceptors are the predominant 
subtype mediating detrusor relaxation. [21] Activation of β3 adrenoceptors has shown to 
relax the detrusor muscle and subsequently lead to the development of the first β3-agonist: 
mirabegron. Mirabegron was introduced in the Netherlands in 2014. Similar success rates as 
for antimuscarinics are described. The most common side-effects are headache and nausea. In 
certain patient groups (e.g. patients with severe hypertension) mirabegron is contraindicated. 
[22] A comparison trial of tolterodine and mirabegron showed that the efficacy was equal, but 
mirabegron showed an improved tolerability. The overall incidence of treatment-emergent 
adverse events was comparable between the two type of drugs, but typical antimuscarinic 
side-effects, such as dry mouth, occurred with a three- or fourfold lower incidence for 
mirabegron than for tolterodine. This favorable tolerability profile of mirabegron might result 
in improved treatment adherence compared with antimuscarinics. [23]
When OAB patients are not responding to conservative or oral treatment botulinum toxin A 
is frequently used in clinical practice. It is an effective and relatively simple procedure to treat 
OAB symptoms. BTA is injected in the bladder wall during a cystoscopic procedure (figure 1). 
12 
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BTA is available in different preparations, however in the Netherlands only onabotulinum toxin 
A (BOTOX) is registered for OAB.
Figure 1: BTA treatment of the bladder
Since the beginning of the 21st century BTA has been frequently used in experimental settings 
or in an off-label fashion for OAB. In August 2011, the U.S. Food and Drug Administration (FDA) 
approved onabotulinum toxin A (BOTOX) injections to treat urinary incontinence in patients 
with neurologic conditions who have neurogenic detrusor overactivity. The FDA expanded 
the approved use of BOTOX to treat adults with idiopathic OAB who cannot use or do not 
adequately respond to anticholinergics.
Botulinum toxin is one of the most potent toxins known. There are seven serotypes of 
botulinum toxin, type A to type G. The most commonly used serotype in the management 
of OAB is type A. [24] The toxin has been known to decrease the release of acetylcholine from 
pre-synaptic membranes, which blocks the transmission of impulses wherever acetylcholine 
is the neurotransmitter. This causes a flaccid paralysis in the muscles supplied by the affected 
motor neurons. In urology, there is emerging evidence that in addition to causing flaccid 
paralysis of the muscle, BTA blocks neuropeptide release from afferent nerves, exocytosis of 
acetylcholine and purines from efferent nerves, and possibly ATP release from the urothelium. 
[25] 
In history, three men contributed decisively to the development of botulinum toxin as a 
therapeutic agent. Christian Kerner 1786–1862, a German physician, was the first to isolate a 
fatty, highly toxic substance from poisoned sausages. In 1897, Emile van Ermengem 1851–1932, 
a Belgian bacteriologist, isolated the bacterium producing the toxin, and by the end of the 
1970s, Alan B Scott, an American ophthalmologist, successfully injected one of his patients 
with botulinum toxin as a treatment for strabismus. The use of botulinum toxin in the lower 
urinary tract was initiated by Dykstra and Sidi [26], who in 1990 pioneered toxin injection into 
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the urethral sphincter to relieve detrusor-sphincter dyssynergia. Schurch et al. [27] reported 
in March 2000 the results of botulinum toxin injection into the bladder to treat urinary 
incontinence in patients with neurogenic detrusor overactivity due to spinal cord injury.  
Since BTA treatment is a relatively simple procedure to perform, but with ongoing development 
of the technique it was not clear what the knowledge concerning BTA treatment is among 
urologists and what they want to learn more about BTA treatment in clinical practice. This is 
studied in chapter 3. After defining these needs by ways of a survey, a literature search was 
performed to answers the defined needs. The study showed that BTA treatment is frequently 
used in urology departments. Since many urologists treat patients with BTA there is a request 
for training in the practical and technical aspects to achieve the best clinical outcome. BTA 
can be applied into the detrusor muscle, submucosally, in a different number of injection 
sites and in different locations in the bladder. More research is necessary to find out which 
injection technique gives the best results. Studies could not define any urodynamic parameter 
obtained prior to BTA treatment to allow preoperative stratifications. The treatment effect 
of BTA injections is temporary and lasts approximately 6–10 months in idiopathic patients. 
[28] Retreatment could be considered when the clinical effect has waned, but the rule is 
that it should be done no sooner than 12 weeks from any prior detrusor injection. Repeated 
injections of BTA into the detrusor muscle are effective and inflammatory infiltration or fibrotic 
activity in the bladder wall has not been observed to date.
Like BTA injections, neuromodulation is also frequently used in clinical practice for refractory 
OAB patients. Neuromodulation is defined as the alteration of nerve activity through targeted 
delivery of a stimulus, such as electrical stimulation, to specific neurological sites in the body. 
[29] The aim of neuromodulation for OAB is to directly induce a therapeutic response or to 
modulate the behavior of the lower urinary tract. Chapter 4 concerns neuromodulation 
treatment. In part one an overview is given of current neuromodulation treatments for OAB; 
how it is done, the known results, and its costs. PTNS, SNS, and the more experimental 
neuromodulation treatments as pudendal nerve stimulation (PNS), and dorsal genital nerve 
stimulation (DGNS) are discussed. 
Part two comprises peripheral neuromodulation with the focus on PTNS. Peripheral 
neuromodulation as a treatment for OAB concerns nerve stimulation of peripheral nerves 
that can influence the behaviour of the lower urinary tract. Examples of these nerves are 
the posterior tibial nerve, the pudendal nerve, and the dorsal genital nerves. These nerves 
originate from the lumbar, sacral, and coccygeal segmental roots from L2 to S4. Afferent and 
efferent fibers from these segmental roots merge in the periphery outside the spinal cord. 
After merging, the nerve fibers continue as combined nerves that have lost their segmental 
innervation pattern. The sciatic nerve is composed of fibers from L4 to S3. The posterior tibial 
nerve is a continuation of the sciatic nerve. The dorsal genital nerve is a continuation of the 
14 
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pudendal nerve and the pudendal nerve is composed of nerve fibers from segmental nerves 
from S2-S4. 
Peripheral neuromodulation of the lower urinary tract has been 
attempted via stimulation of those nerves that are related or involved in 
pelvic organ innervation. The history of PTNS started in the East. It is an 
ancient Chinese custom to perform acupuncture of the lower leg. With 
this technique, developed in China over 5,000 years ago, the “energetic 
harmony” of the urogenital tract might be restored by way of stimulation 
of specific points. Wilhelmus ten Rhyne (1647-1700) was a Dutch physician 
who was employed by the Dutch East India Company in 1673 where he 
encountered eastern traditional medicine. In 1683 he published a book 
entitled “Dissertatio de Arthritide: Mantissa Schematica: De Acupunctura: 
Et Orationes Tres”. [30] He wrote about the art of needling for treating 
diseases including those of the lower urinary tract. He called this 
technique ‘Acupunctura’ and it was the first Western detailed study on 
that matter. The similarities of PTNS and ‘Acupunctura’ are so striking that 
it seems reasonable to assume that they have a similar pathophysiological 
working mechanism. In part three SNS treatment is described in a practical 
way. Nowadays SNS is often performed in a two stage-technique with a 
quadripolar lead with self-anchoring tines, first described by Spinelli et al 
in 2003. [31] The first SNS implant in a urological patient was performed 
by Tanagho and Schmidt at the University of California in San Francisco 
in 1982. After that, in 1994 InterStim received the CE mark for treatment 
of chronic functional disorders of the pelvis, lower urinary, and intestinal 
tract in Europe. In 1997 Interstim received a FDA approval for treatment of 
urgency urinary incontinence in the USA which was expanded in 1999 for 
treatment of symptoms of urgency-frequency and urinary retention. 
This thesis also comprises new developments in OAB treatment, which are promising for 
the future. Chapter 5 concerns experimental neuromodulation. Part one describes a pilot 
study on subject controlled, on-demand, DGNS to treat urgency urinary incontinence. This 
feasibility study indicates that subject controlled, on-demand, DGNS, using a percutaneously 
placed electrode is possible over a longer period of time, in a home setting, with a positive 
Figure 2: peripheral nerves of the leg
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General Introduction and outline of this thesis
effect on non-neurogenic overactive bladder symptoms. Although the placement is an easy 
procedure, it is difficult to fixate the electrode to keep it in the correct position. Improvements 
in hardware, like an electrode that can fixate itself in the surrounding tissue and an easy to 
control stimulator, are necessary to make subject controlled, on-demand, DGNS a treatment 
possibility in the future. Part two describes a study to a new implant for tibial nerve stimulation 
(TNS) treatment. This implant would make it possible for patients to apply TNS treatment on 
demand, everywhere, and without the need to insert a needle. In this study TNS delivered 
through an implant gave at least comparable results to conventional PTNS and SNS. 
16 
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Abstract
Introduction
Lower urinary tract symptoms and urinary incontinence may have major impact on quality 
of life. However, not all individuals with urological complaints seek medical advice. The aim 
of this study is to investigate the prevalence of LUTS in young otherwise healthy nulligravid 
females and the accompanying burden.
Methods 
A total of 159 young presumably healthy female medical students aged 18-30 years were 
recruited at their university. All completed the International Consultation on Incontinence 
Modular Questionnaire for Female Lower Urinary Tract Symptoms. The prevalence of LUTS 
and the accompanying burden were measured. Correlation between symptoms and bother 
was analysed using Spearman’s rho.
Results 
A prevalence of LUTS was found in 94.3% of individuals, urgency at least sometimes in 14.5%, 
and hesitancy in 14.5%. Nocturia once a night was present in 18.2%; no participant reported 
nocturia > 2 times. Involuntarily loss of urine was reported by 20.1% but in no individual > 2 
times a week. For all bother scores the median value was 0; the highest bother score was for 
urgency. For all questions a positive correlation was found between symptoms and bother; a 
strong correlation was found for bladder pain, urgency UI, stress UI and overall UI. 
Conclusions 
In a presumably healthy population of young nulligravid women the prevalence of LUTS and 
UI was high, but with relatively low bother. 
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Introduction
Lower urinary tract symptoms (LUTS) and urinary incontinence (UI) may have major impact on 
quality of life. However, not all individuals with urological complaints seek medical advice. The 
exact prevalence of complaints probably varies with age and sex, and the prevalence of LUTS/
UI among young otherwise healthy nulligravid women is not been studied extensively yet. 
Earlier, in our center, we investigated LUTS in young otherwise healthy men, compared with 
hypospadias patients as a control group, using the International Prostate Symptom Score (IPSS) 
and found an unexpectedly high prevalence of LUTS: 7% had moderate to severe LUTS (IPSS 
>7)[1]. These findings prompted initiation of a comparable study among young nulligravid 
females.
Knowledge on the prevalence of LUTS in healthy young nulligravid women may be important 
to establish what can be considered as ‘normal’ in the general population; this is particularly 
important in the context of therapeutic studies. Alternatively, there may be a ‘hidden’ health 
problem requiring attention. Therefore, the present study aims to establish the prevalence 
of LUTS in young otherwise healthy nulligravid females and, especially, the accompanying 
burden.
Methods
The study was approved by the local ethical committee and written informed consent was 
obtained from all participants. Between April 2011 and June 2011 young presumably healthy 
nulligravid female medical students (aged 18-30 years) were recruited at the university by oral 
announcement of this study. Those interested in participating were invited to our urology 
department. Excluded were females aged <18 or >30, with a history of urological disease, 
neurological disease, present symptoms of urinary tract infection (UTI), pregnancy or a 
pregnancy in the past.
All subjects were asked to fill out the International Consultation on Incontinence Modular 
Questionnaire for Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) questionnaire[2]. The 
questionnaire consists of four questions on bladder filling, three on voiding and five on 
incontinence. Each question concerning urinary symptoms allows the patient to choose 
one out of five answers indicating increasing frequency of the particular symptom: ‘never’ (0), 
‘occasionally’(1), ‘sometimes’ (2), ‘most of the time’ (3), and ‘always’ (4). There is no scoring system 
or established cut-off points for the ICIQ-FLUTS. We considered a score ≥ 2 (at least sometimes) 
as positive for having the symptom. Frequency was defined as >8 micturitions a day. The total 
sum score of the ICIQ-FLUTS ranges from 0-48 (asymptomatic to very symptomatic). Nocturia 
22 
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≥ 2, day time frequency ≥ 9, and urgency were considered to be storage symptoms whereas 
hesitancy, straining, and intermittency were considered to be voiding symptoms.
Each question on symptoms was linked to a question on bother. There are no established 
cut-off points for the bother score. All subjects also filled in a questionnaire concerning the 
exclusion criteria: age, urological history, neurological history, pregnancy or pregnancy in the 
past, present UTI.
Statistical analysis was performed with the SPSS version 20. Mean values with standard 
deviation (SD) and median values with interquartile ranges (IQR) were calculated. Correlations 
were analysed using Spearman’s rho. A p-value < 0.05 was considered significant. A correlation 
> 0.7 was considered to be a strong correlation.
Results
Initially, 178 students came voluntarily to the urology department to participate. 19 students 
were excluded: 1 had symptoms of a UTI, 1 had had a pregnancy in the past, 3 were aged ≥ 30 
years, 1 was known with a neurological disease, and 13 did not fill out the entire questionnaire. 
The median age of the participants was 22 (IQR 20-24) years. None of the students had sought 
medical advice for their urinary symptoms or were planning to do so after filling in this 
questionnaire. 
Outcomes of the ICIQ-FLUTS are presented in Table 1, except outcomes of micturition frequency 
and Nocturia. Nocturia once a night was present in 29/159 (18.2%) and twice a night in 2/159 
(1.3 %); no participant reported nocturia > 2 times a night. Concerning micturition frequency, 
113/159 women (71.1%) voided 1-6 times a day, 31/159 (19.5%) 7-8 times a day, 13/159 (8.2%) 
9-10 times a day, and 2/159 (1.3%) 11-12 times a day. Nine/159 (5.7%) women had no symptom 
at all, i.e. reported never to each question. Urgency and hesitancy were both reported at least 
sometimes (= sometimes, most of the time or always) in 23/159 (14.5%) of the women. Bladder 
pain was experienced at least sometimes by 6/159 women (3.9%). Involuntarily loss of urine 
was reported by 32/159 (20.1 %) women, by 27/159 (17.0%) once a week or less, and by 5/159 
(3.1%) twice a week. None of the women had involuntary loss of urine more than twice a week. 
Participants with involuntary loss of urine (n=32) were divided into subgroups according to 
the type of incontinence. Of all participants, 16/32 (50%) had both stress and urgency UI, 5/32 
(15.6%) had urgency UI only, 4/32 (12.5%) had stress UI only, and 4/32 (12.5%) had urgency UI 
and unexplained UI. One woman had all three types of UI and 2/32 (6.2%) answered negative 
to all three types of UI. No participant had nocturnal enuresis. 
At least most of the time (= most of the time or always) was reported for urgency by 5/159 (3,1%) 
of the women, for hesitancy by 4/159 (2,5%), for straining 2/159 (1,3%) and for intermittency 
1/159 (0.6%) woman experienced this at least most of the time. 
23 
Hidden prevalence of lower urinary tract symptoms in healthy nulligravid young women
C
h
ap
te
r 
2
Table 1: Outcomes of the International Consultation on Incontinence Modular Questionnaire for Female 
Lower Urinary Tract Symptoms questionnaire, expressed as frequency of occurrence. 
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Never 
Point score (0)
123
77.4%
51
32.1%
60
37.7%
110
69.2%
124
78.0%
126
79.2%
113
71.1%
156
98.1%
159
100%
Occasionally  
Point score (1)
30
18.9%
85
53.5%
76
47.8%
39
24.5%
33
20.8%
27
17.0%
41
25.8%
3
1.9%
0
Sometimes  
Point score (2)
6
3.8%
18
11.3%
19
11.9%
8
5.0%
1
0.6%
6
3.8%
5
3.1%
0 0
Most of the time  
Point score (3)
0 3
1.9%
4
2.5%
1
0.6%
0 0 0 0 0
Always
Point score  (4)
0 2
1.3%
0 1
0.6%
1
0.6%
0 0 0 0
Any symptom 36
22.6%
107
67.9%
101
62.3%
49
30.8%
35
22.0%
33
20.8%
46
28.9%
3
1.9%
0
At least 
sometimes
(Point score ≥2)
6
3.8%
23
14.5%
23
14.5%
10
6.2%
2
1.2%
6
3.8%
5
3.1%
0
0%
0
0%
Range 
(point score)
0-2 0-4 0-3 0-4 0-4 0-2 0-2 0-1
Mean 
(point score)
0.26
(SD ±0.5)
0.87
(SD ±0.8)
0.79
(SD ±0.8)
0.39
(SD ±0.7)
0.25
(SD ±0.5)
0.25
(SD ±0.5)
0.32
(SD ±0.5)
0.02
(SD ±0.1)
0
Median
(point score)
0
(IQR 0-0)
1
(IQR 0-1)
1
(IQR 0-1)
0
(IQR 0-1)
0
(IQR 0-0)
0
(IQR 0-0)
0
(IQR 0-1)
0
(IQR 0-0)
0
SD = standard deviation; IQR = interquartile range
The scores of the different categories were summed, i.e. those of storage subscales, and of 
voiding and incontinence. The median sum of scores on storage complaints was 1 (occasionally, 
IQR 1-2), on voiding complaints 1 (occasionally, IQR 1-2), and on incontinence 0 (never, IQR 0-1). 
The median total score was 4/48 (IQR 2-5). 
The outcome of the bother score is shown in Table 2. For all bother scores the median value 
was 0. The highest bother score was for urgency. 
Table 3 presents the bother scores of women with a symptom score ≥2 (at least sometimes), 
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a symptom score of ≥3 (at least most of the time), nocturia and frequency. The highest bother 
score was found in women with incontinence. 
Table 2: Bother score as measured by the International Consultation on Incontinence. Modular 
Questionnaire for Female Lower Urinary Tract Symptoms questionnaire N=159
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0 135
84.9%
121
76.1%
92
57.9%
118
74.2%
119
74.8%
132
83.0%
144
90.6%
135
84.9%
129
81.1%
121
76.1%
156
98.1%
159
100%
1 7
4.4%
13
8.2%
24
15.1%
15
9.4%
22
13.8%
13
8.2%
6
3.8%
6
3.8%
10
6.3%
13
8.2%
- -
2 7
4.4%
13
8.2%
17
10.7%
9
5.7%
9
5.7%
8
5.0%
6
3.8%
3
1.9%
7
4.4%
8
5.0%
2
1.3%
-
3 3
1.9%
5
3.1%
12
7.5%
6
3.8%
3
1.9%
2
1.3%
1
0.6%
3
1.9%
4,
2.5%
7
4.4%
- -
4 2
1.3%
4
2.5%
5
3.1%
2
1.3%
3
1.9%
2
1.3%
1
0.6%
3
1.9%
1
0.6%
4
2.5%
- -
5 2
1.3%
1
0.6%
2
1.3%
2
1.3%
2
1.3%
1
0.6%
1
0.6%
4
2.5%
1
0.6%
1
0.6%
- -
6 1
0.6%
1
0.6%
4
2.5%
3
1.9%
1
0.6%
- - - 2
1.3%
3
1.9%
- -
7 2
1.3%
1
0.6%
- 2
1.3%
- - - 5
3.1%
3
1.9%
- - -
8 - - 2
1.3%
2
1.3%
- 1
0.6%
- - 2
1.3%
2
1.3%
1
0.6%
-
9 - - - - - - - - - - - -
10 - - 1
0.6%
- - - - - - - - -
>0 24
15.1%
38
23.9%
67
42.1%
41
25.8%
40
25.2%
27
17.0%
15
9.4%
24
15.1%
30
18.9%
38
23.9%
3
1.9%
0
range 0-7 0-7 0-10 0-8 0-6 0-8 0-5 0-7 0-8 0-8 0-8
mean 0.43 
(SD
±1.3)
0.55 
(SD 
±1.2)
1.09 
(SD 
±1.8)
0.74 
(SD 
±1.7)
0.48 
(SD 
±1.1)
0.35 
(SD 
±1.0)
0.19 
(SD 
±0.7)
0.55 
(SD 
±1.6)
0.59 
(SD 
±1.6)
0.66 
(SD 
±1.5)
0.08 
(SD 
±0.7)
0
median 0
(IQR  
0-0)
0
(IQR  
0-0)
0
(IQR  
0-0)
0
(IQR  
0-1)
0
(IQR  
0-1)
0
(IQR  
0-0)
0
(IQR  
0-0)
0
(IQR  
0-0)
0
(IQR  
0-0)
0
(IQR  
0-0)
0
(IQR  
0-0)
0
SD = standard deviation; IQR = interquartile range
Tab
le 3: Bother scores of subjects w
ith a sym
ptom
 score ≥
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m
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es a night, 
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Q
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s questionnaire. 
Nocturia ≥1 times a night 
Nocturia ≥2 times a night 
Pain ≥2 
Pain ≥3
Urgency ≥2 
Urgency ≥3
Frequency ≥9 times a day
Frequency ≥11 times a day
Hesitation ≥2 
Hesitation ≥3
Straining ≥2 
Straining ≥3
Intermitterency ≥2 
Intermitterency ≥3
Urinary incontinence ≥2 
Urinary incontinence ≥3
Urgency urinary incontinence ≥2 
Urgency urinary incontinence ≥3
Stress urinary incontinence ≥2 
Stress urinary incontinence ≥3
Unexplained urinary incontinence ≥2 
Unexplained urinary incontinence ≥3
Nocturnal enuresis ≥2 
Nocturnal enuresis ≥3
N
=
31
2
6
0
23
5
15
2
23
4
10
2
2
1
5
0
6
0
5
0
0
0
0
0
Range
Botherscore
0-7
0-7
1-7
-
0-10
3-10
0-8
2-8
0-6
0-6
0-8
0-8
0-4
-
5-7
-
3-8
-
1-8
-
-
-
-
-
M
ean
Botherscore
1.9
(SD
 
±
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±
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3.2
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±
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6.6
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1.5
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±1.9)
3(SD
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2.0
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±
2.6)
4(SD
±
5.7)
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-
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-
-
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6
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3
(IQ
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0-6)
-
1
(IQ
R  
0-3)
3
(IQ
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0.3-
5.8
1
(IQ
R
0-4)
4
-
7
(IQ
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6-7)
-
7
(IQ
R 
5.3-8)
-
6        
(IQ
R  
2-8)
-
-
-
-
-
SD
=
 standard deviation; IQ
R =
 interquartile range.
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Nocturia ≥1 times a night 
Nocturia ≥2 times a night 
Pain ≥2 
Pain ≥3
Urgency ≥2 
Urgency ≥3
Frequency ≥9 times a day
Frequency ≥11 times a day
Hesitation ≥2 
Hesitation ≥3
Straining ≥2 
Straining ≥3
Intermitterency ≥2 
Intermitterency ≥3
Urinary incontinence ≥2 
Urinary incontinence ≥3
Urgency urinary incontinence ≥2 
Urgency urinary incontinence ≥3
Stress urinary incontinence ≥2 
Stress urinary incontinence ≥3
Unexplained urinary incontinence ≥2 
Unexplained urinary incontinence ≥3
Nocturnal enuresis ≥2 
Nocturnal enuresis ≥3
N
=
31
2
6
0
23
5
15
2
23
4
10
2
2
1
5
0
6
0
5
0
0
0
0
0
Range
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0-7
0-7
1-7
-
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-
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-
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-
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For all questions a positive correlation was found between symptoms and bother. A strong 
correlation (> 0.7) was found for bladder pain, urgency UI, stress UI and overall UI (Table 4). 
Table 4: Correlation between symptoms and bother measured with Spearman’s rho.
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Spearman’s 
rho
0.68
(p 
<0.01)
0.93
(p 
<0.01)
0.63
(p 
<0.01)
0.40
(p 
<0.01)
0.41
(p 
<0.01)
0.61
(p 
<0.01)
0.61
(p 
<0.01)
0.85
(p 
<0.01)
0.91
(p 
<0.01)
0.88
(p 
<0.01)
0.66
(p 
<0.01)
-
Discussion
In this group of young healthy nulligravid women the vast majority (94.3 %) reported some kind 
of LUTS or UI; only 5.7% of women had no symptoms at all. Furthermore, 40.9% of the group 
had one or more complaints at least sometimes. When comparing these results with those 
of similar studies among young women, we found more incontinence, urgency, hesitancy 
and straining, but less nocturia, frequency and intermittency [3-9]. However, the results of 
earlier studies are not consistent. For example, the prevalence of UI is reported to range from 
3.4-20.1%, for urgency from 3-19.5%, for hesitancy from 9.3-14.1%, for straining from 1.5-14.1%, 
for nocturia from 9.5-9%, for frequency from 7-46.1% and for intermittency from 1.6-31.5%[3-
9]. In the present study, LUTS was defined as being present when it was reported to occur 
‘at least sometimes’. In other studies different definitions/thresholds, different surveys and 
different administration techniques were used. For example, Liao et al. defined the presence 
of LUTS as the self-reported occurrence during the past 12 months, using a self-developed 
(paper) questionnaire[6]. Irwin et al. asked whether or not symptoms were experienced 
using a self-developed questionnaire; their subjects were interviewed during a telephone 
call [5]. Chuang et al. used the IPSS questionnaire and face-to-face interviews with their 
participants[3]. However, the grade of symptom severity was often not adequately described 
or differed between these studies. Moreover, the use of different questionnaires, definitions 
and methodology make comparison with other studies and interpretation of results difficult. 
Furthermore, study population differed between studies regarding age, ethnicity and social 
background. 
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The present study shows that 9.5% of the subjects had a daytime frequency of ≥ 9, whereas 
others have reported a frequency ranging from 7-57.1%[3, 5-7, 9]. However, these results should 
be interpreted with caution because no information on daily fluid intake was available in the 
present nor in the other studies. 
In our group, UI of any type and frequency was reported by 20.1% (with 3.1% experiencing 
urinary loss at least twice a week), whereas others have reported 3.4-20.1% [4-9]. 
However, definitions may have varied between these studies. In the present study urgency UI 
was found slightly more often than stress UI; this might be because the group was aged ≤ 30 
years and nulligravid. A study among young nulligravid women conducted by O’Halloran et 
al. revealed the opposite: slightly more stress UI than urgency UI [8]. A remarkable finding is 
that two women who indicated to experience UI at least sometimes (more often than never), 
answered negative to all types of UI when differentiating into subgroups; we have no clear 
explanation for this finding. 
Nocturia once a night was found in 18.2% of our participants and twice a night in 1.3 %; 
no participant reported nocturia > 2 times a night. The clinical relevance of nocturia for 
individuals who have only one episode per night is yet to be determined. However, given the 
large decrease in the prevalence of nocturia when the definition was changed from at least 1 
micturition per night to 2 or more micturitions a night, suggests that 1 micturition per night 
is part of the normal spectrum. Other studies comparing nocturia with bother showed that 1 
void per night does not identify persons with bothersome nocturia and, thus, is not a suitable 
criterion for clinically relevant nocturia [10, 11].
In the present study, for all questions a positive correlation was found between symptoms and 
bother, most strongly for bladder pain and urgency UI. Bother scores were highest in women 
experiencing at least sometimes incontinence and storage symptoms, whereas those with 
voiding symptoms had relatively low bother scores. The presence of urgency UI had slightly 
more influence on bother scores than having stress UI. It is reported that women with UI and 
overactive bladder symptoms score lower on physical and mental health scores than women 
without these symptoms [8, 12]. Studies describing the effect of UI on the quality of life show 
that mixed UI is more bothersome than urgency UI or stress UI alone, and that urgency UI 
alone is more bothersome than stress UI alone [12-15].
In general, our participants scored higher on the symptom scores than on the bother scores; 
this might imply that their perceived symptoms were not always annoying but may have been 
interpreted as physiological. In the present study, if a symptom was scored ≥ sometimes, that 
symptom was defined as (relevantly) present. Choosing another threshold, for instance ‘most 
of the time’ of course lowers the prevalence. In our opinion, a sometimes occurring symptom 
is relevant. And as expected, if a symptom occurs more often, the bother scores are higher. 
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However, as there is no an established cut-off point for the ICIQ questionnaires, this issue 
remains debatable. 
Taking into account that the present research population consisted of females not seeking 
medical advice for LUTS, the question arises whether a symptom should be called a complaint 
or whether it should be considered as ‘normal’. The fact that the bother scores were relatively 
low indicates that not all symptoms were a complaint. On the other hand, reluctance and 
shame may have played a role in not seeking medical advice. 
The results of the present study should be viewed within the context of its limitations. First, 
only medical students were invited to participate, mainly for logistical reasons. However, this 
group may not be representative for the general population, mainly because of a higher 
educational level and (perhaps) social values that might differ from the general population. 
O’Halloran et al [8], found that in a population of young nulligravid women, incontinence was 
slightly more common in students than in nonstudents. In our group of medical students, 
some additional knowledge/training in urology and awareness of urological signs and 
symptoms can be assumed. These factors may have influenced the outcomes. 
A limitation concerning other factors that could influence LUTS is that we have no information 
about sexual activity, BMI and smoking or drugs use. 
Another limitation involves the use of self-reports to measure LUTS. There is evidence that self-
reports are vulnerable to inaccuracy relative to the criterion standard of a physician diagnosis 
based on assessment of patient history and urodynamic evaluation [16, 17]. However, the use of 
physician diagnosis would introduce a degree of subjectivity and changes in the bother scale. 
Also, our results might have differed slightly had information been collected by telephone, 
mail, or via face-to-face interviews [18, 19]. In addition, because we recruited participants via an 
announcement in the medical school, no information is available on the response rate. Some 
individuals who were invited declined to participate, possibly creating some selection bias. We 
have no further information on the candidates who did not participate.
In conclusion, in this presumably healthy group of young nulligravid women the prevalence of 
LUTS and UI is high, although with relatively low bother. These findings should be taken into 
account in therapeutic studies in a comparable age group. Furthermore, the presence of LUTS 
or UI in this study population appears to be no reason to seek medical advice.
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Abstract
Introduction
To give an overview of the literature concerning the clinical practice of Botulinum toxin A(BTA) 
treatment to meet the needs and knowledge of urologists. 
Methods
A literature search was performed to BTA treatment, together with a survey amongst Dutch 
urologist.
Results
The registration trials used strict in- and exclusion criteria, a standardized application technique 
and follow up. The approval for BTA is based on these trials but differs from country to country. 
BTA was already used before these approvals, with different application techniques. Published 
manuscripts about application techniques (trigone sparing/suburothelial injections/
intradetrusor injections) show different outcomes. In literature there is no positive or negative 
predictor found with a preoperatively urodynamic investigation. It is shown that retreatment 
does not cause inflammatory infiltration or fibrosis in the bladder wall. The survey showed that 
in 96% of the urology departments BTA is used. Urodynamic investigation is requested by 87% 
of urologists before the treatment. Although it is regarded as an easy-to-learn procedure 60% 
of urologists would like training in practical aspects.
Conclusions: 
No firm data exist about the technique of application with consequently the most optimal 
results. BTA treatment is regarded as an easy-to-learn, but still there is a request for training in 
practical treatment aspects. 
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Introduction
Botulinum Toxin A (BTA) is used frequently in clinical practice, it’s an effective and relatively 
simple procedure to treat overactive bladder (OAB) symptoms and detrusor overactivity (DO).
[1-4] Since the beginning of the 21st century BTA has been used in experimental settings or 
in an off-label fashion for OAB. In august 2011 the U.S. Food and Drug Administration (FDA) 
approved onabotulinum toxin A (BOTOX) injections to treat urinary incontinence (UI) in 
people with neurologic conditions (e.g., spinal cord injury (SCI) and multiple sclerosis (MS) who 
have neurogenic detrusor overactivity (NDO). The FDA expanded the approved use of BOTOX 
to treat adults with idiopathic OAB (iOAB) who cannot use or do not adequately respond to 
anticholinergics.[5] The FDA approval is based on 4 large multicentre trials.[1-4] These trials 
demonstrate a superior efficacy of BOTOX compared to placebo. In NDO the efficacy of 200U 
and 300U are comparable and in iOAB 100U have the same efficacy as 150U.
In Europe the system of approval and registration is different. Some medical products are 
approved by a centralized authorization procedure from the European Medicines Agency 
(EMA), others like BOTOX are approved by national authorization procedures.[6] The Irish 
Medicines Board approved BOTOX for the treatment of iOAB with symptoms of UI, urgency and 
frequency in adults who have an inadequate response to, or are intolerant of, anticholinergic 
medication and for UI in adults with NDO resulting from neurogenic bladder due to stable 
sub-cervical SCI, or MS. Ireland has served as the reference member state in the European 
mutual recognition procedure for 13 countries: Austria, Belgium, Denmark, Finland, Germany, 
Greece, Iceland, Italy, Luxemburg, Norway, Portugal, Spain and Sweden.[7] In the United 
Kingdom (UK) BOTOX is approved to treat UI in adults due to NDO. This approval is based 
on the large phase 3 trials,[3, 4] which included only patients with NDO due to SCI or MS but 
the national regulatory authorities agreed that positive results from these trials in these two 
indications would allow a broad indication in NDO regardless of its etiology.[8] BOTOX has also 
been licensed in the UK for the management of bladder dysfunctions in adult patients with 
OAB with symptoms of UI, urgency and frequency and who are not adequately managed with 
anticholinergics. 
In some countries like Ireland approval is given for those indications that have clear proven 
effect. It is not possible to expand this for similar indications or diseases. This also goes to some 
extent for the applied technique. Strict interpretation implies only applicable for the same 
indications and with the same technique. Because in Europe the approval and registration 
differs from country to country as listed above there can be differences between countries in 
indication and application techniques of BOTOX. The question arises whether these differences 
in technique and indications will affect the efficacy of the treatment. Recently some renowned 
experts published about the technical aspects of the BOTOX procedure. They listed differences 
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in application of the injected dose, the injection mapping, the injected volume per site, the 
needle type and the type of anesthesia.[9] In France a group of experts made a guideline for 
the practical usage of BOTOX for refractory iOAB management.[10]
In the Netherlands BOTOX is also registered for patients with UI due to NDO or for patients 
with an OAB with symptoms of UI, urgency and frequency who not adequately respond to 
anticholinergics or their use is contra-indicated.[11] 
Because there is ongoing development of the technique, it is not clear what the knowledge 
and needs are among urologists about application of BTA in clinical practice. Therefore 
a questionnaire was send by email to all registered urologists in the Netherlands. The 
questionnaire consisted of questions concerning various aspects of BTA treatment and if so, 
what kind of training they would like to receive. This manuscript reflects the results of this 
questionnaire within the latest development of BTA application in international urological 
practice. 
Methods
A questionnaire was send to all registered urologists in the Netherlands and a literature search 
by Pubmed to BTA treatment was performed. 
Results
Survey
The questionnaire was sent in September 2013 to 491 Dutch urologists and urologists in 
training, working in approximately 100 urology Departments. Ninety-five (19%) responded. 
The responders are urologists with interest in functional urology. They represent approximately 
75% of all Dutch urological clinics. Responses showed that in 96% of the responding urological 
clinics BTA is used as a treatment for OAB as well in neurogenic as in non-neurogenic patients. 
In 72% more than 1 caretaker in the department performs BTA treatment. An urodynamic 
investigation (UDI) is requested by 83% of the urologists before the first BTA treatment, in case 
of repeat treatment 57% requests a next UDI only on indication, 4% requests an UDI before 
every BTA treatment. Thirteen% does not perform an UDI prior to BTA treatment. 
Ninety-three % would like to receive training in the theoretical and/or practical aspects of 
BTA treatment. This training would preferable as a theoretical training session by 38% of the 
urologists, 24% prefers a proctor session, 67% a workshop during the Dutch urology meeting, 
42% a web based e-learning and 31% feels it’s sufficient to be trained during residency. 
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Discussion 
The answers to the questionnaire show that almost all the urology departments use BTA in 
clinical practice without being especially trained for this procedure. Therefore we assume 
that this is an easy-to-learn procedure for a urologist. When this questionnaire was sent BTA 
treatment was still off-label, implying it’s a clinical driven therapy. The urologist probable 
believes in this treatment since patients are treated with BTA even without registration for OAB. 
Nowadays BOTOX is the only approved formulation of BTA. However, the other formulation 
abobotulinumtoxin A (DYSPORT) is also used in clinical practice in the Netherlands. The 
decision which formulation is used is often based on local pharmacy regulations and financial 
considerations. Licensing is undoubtedly having a significant influence on this practice. To 
our knowledge there are no randomized, prospective studies directly comparing different 
formulations of BTA. Ravindra [12], published a retrospective, non-randomised study comparing 
BOTOX to DYSPORT for iOAB treatment after their department switched from formulation used. 
They found similar results, with no difference in duration of effect, but the DYSPORT cohort had 
almost twice the rate of symptomatic urinary retention (23 vs 42%) requiring CIC. Stoehrer[13] 
published a retrospective study comparing BOTOX to DYSPORT for NDO treatment. He didn’t 
observe any differences between the two formulations of BTA. 
Despite many urologists use BTA there still are requests for training to improve the technique 
with the best clinical outcome, for providing good patient information and to have more 
background knowledge. The questionnaire also shows that the urologists do want training of 
the technique, but not in a very time-consuming way. 
BTA treatment was applied in various ways off-label or in research settings long before there 
was an approval in the USA or Europe. Moreover, the registration details for BOTOX application 
is slightly different among countries. Without a fixed and rigid application regime, much 
variation in indication and technique is possible. In the Netherlands and internationally the 
application techniques and follow-up are scrutinized and analyzed for predictive factors, 
other indications, treatment regimes etcetera. Consequently, publications from different 
countries are available to optimize the various techniques.[14-18] But still there is no consensus 
concerning the best application technique. 
The registration trials, used a standardized application technique. For iOAB 20, 0.5ml 
intradetrusor injections, and for neurogenic patients 30, 1ml intradetrusor injections were 
used both trigone-sparing. This does not imply that everybody uses the same technique as 
in these trials. Karsenty [9] performed a review among 13 experts from 10 countries about 
current clinical practice. It showed differences in units of BTA, injection mapping, injection 
volume, the needle and cystoscope that is used. Literature shows that BTA can be applied 
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using a various number and amount of injections, trigone-sparing or not, and suburothelial or 
intradetrusor injections. 
Trigone-sparing injections or including the trigone
The first report of intravesical BTA injection describes a trigone-sparing injection distribution 
because of the theoretical risk of inducing vesicoureteral reflux (VUR). Karsenty et al[15], 
injected 12 women with idiopathic DO (iDO) with 200u BTA in 10, 1ml injections, no VUR was 
seen. Kuo et al,[17] performed a trial with 105 patients with urodynamic proven iDO. Patients 
were divided into 3 treatment groups. Group A received injections in the bladder body, group 
B in the bladder body and in the trigone, and group C in the bladder base and in the trigone. 
Hundred units of BOTOX were given in 20, 0.5ml injections in the first two groups and in 10, 
1ml injections in the third group. There were no significant differences in results or in incidence 
of adverse events among the subgroups. No VUR was found. Abdel-meguid[14] performed 
a study in 38 patients with refractory NDO distributed over 2 treatment groups. One group 
received BTA injections including the trigone and the other trigone-sparing injections. In the 
short term all parameters improved significantly in each treatment group. The superiority of 
including rather than excluding the trigone was significant. At this moment different studies 
show different outcomes. But the former theory that injection into the trigone will induce VUR 
has been depraved.
Suburothelial injections or intradetrusor injections
There are few studies performed comparing suburothelial injections to intradetrusor 
injections. Kuo, [16] performed a study with 45 patients with iDO refractory to antimuscarinic 
therapy. Patients were randomly allocated to receive 100U BOTOX injected into the detrusor, 
suburothelial or in the bladder base. He concluded that at a dose of 100U, detrusor and 
suburothelial injection of BOTOX had similar initial effects on iDO. However, the effective 
therapeutic duration was significantly longer in patients receiving suburothelial and 
intradetrusor injections compared to bladder base injections. Bladder base injections of BOTOX 
had a lower incidence of difficult urination and increased PVR. Samal[18], performed a study 
with 23 patients with NDO. Patients were randomly assigned and treated with 300U of BTA 
either with suburothelial injections or intradetrusor injections. Comparing the results of both 
groups did not reveal any significant difference in the number of UI episodes, urodynamic 
parameters, number of catheterizations or duration of effectiveness. A significant difference 
(p=0.007) in favor of the suburothelial group was found for the voided volume/catheterized 
volume. 
Distribution
Karsenty’s article [9] lists the variation in concentration and the number of injections. Distribution 
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of the toxin after injection is difficult to ascertain. Mehnert et al[19] treated 6 patients receiving 
300U of BOTOX, containing gadolinium in the injecting fluid for identification by magnetic 
resonance imaging. When descriptively comparing the two different treatment modalities (30 
vs.10 injection sites) there was a similar amount of contrast agent found in the target area (85.7 
vs.79.2%) and a similar percentual coverage of detrusor volume with the contrast agent (33.3 
vs.25.3%). This suggests no difference in distribution between 10 and 30 injections.
A recent study in Guinea pigs [20] suggested that the same dose of BTA diluted in a higher 
volume of saline generates more cleaved SNAP-25 and at more distant places from the 
injection side than diluted in a low volume indicating a more widespread diffusion of the 
toxin. This suggests a favorable outcome in distribution if the BTA is diluted in a higher volume. 
Urodynamic investigation
Eighty-seven% of the urologists perform a UDI before BTA treatment. In case of iOAB treatment 
the large phase 3 clinical trials did not perform a UDI prior to the treatment. Patients were 
included based on the amount of UUI episodes and frequency. In case of NDO the trials 
performed a UDI to diagnose NDO and to evaluate the effect of BOTOX on the maximum 
detrusor pressure. Little is written about the predictive value of an UDI prior to BTA treatment. 
Schmid [21] did not observe a significant difference in the success rate of BTA treatment 
between iOAB patients with or without DO. But the non-responders to BTA treatment 
all revealed a low pretreatment detrusor compliance (DC) (less than 10 ml/cm H
2
O) and a 
maximum cystometric bladder capacity of less than 100 ml due to bladder wall fibrosis, as 
demonstrated by detrusor biopsies.
Grosse [22] presented an abstract about the predictive value of an UDI for BTA treatment in 
patients with NDO and concluded that none of the parameters used to describe detrusor 
function and NDO were predictive for therapeutic success. Rovner [23] pooled the results 
from the two Phase III trials [3, 4] for further urodynamic analysis. No relevant differences in 
clinical outcomes or urodynamic improvements after BOTOX treatment between patients 
with NDO and low (≤20 ml/cmH2O) or high (≥20 ml/cmH2O) DC at baseline were observed. In 
another study Rovner [24] compared the effect of BOTOX treatment in patients with iOAB and 
UUI, with or without DO. No differences in outcomes between those with and those without 
baseline DO were observed, therefore successful iOAB treatment with BOTOX does not appear 
to be related to pre-treatment finding of DO. 
Follow up 
In the large clinical trials follow up to evaluate the BOTOX treatment in iOAB patients was 
performed with a 3-day bladder diary, the treatment benefit scale (TBS), Quality of life (QoL) 
questionnaires, PVR and initiation of CIC.[1, 2] In the large clinical studies with BOTOX treatment 
40 
CHAPTER 3
for NDO, a 7-day bladder diary and urodynamics 6 weeks after treatment was used to evaluate 
the treatment.[3, 4] In clinical practice a PVR at 2 weeks is usually assessed in combination with 
patient communication regarding changes in their symptoms or improvements in their QoL 
and after that, further follow up is usually patient/symptom directed.[9] The French guideline, 
suggests that after the first injection, an appointment must be scheduled within 3 months. 
Micturition diary, uroflowmetry, PVR measurement and urine culture should be evaluated.[10]
CIC
In the large clinical trials 6,1%-6,9% of the patients with iOAB, treated with BOTOX 100U, had to 
initiate CIC after treatment.[1, 2] In patients with UI due to NDO of whom did not catheterize 
at baseline 30%-35% initiated CIC after treatment.[3, 4] Comparing the percentage of patients 
initiated CIC is difficult, since different trials, have different cut-off points for initiating CIC. In 
the iOAB patients it was depending on symptoms or if the PVR was >350ml. In neurogenic 
patients it was depending on the physician’s clinical judgment. The French guideline suggests 
starting CIC in the case of a symptomatic PVR and/or a PVR > 200 ml.[10] 
Retreatment
In the large clinical trials patients were offered retreatment after 12 weeks. The French 
guideline[10] advises that a new injection may be considered when the clinical benefit of 
the previous injection diminishes but a period of 3 months must elapse between each 
injection. Also the manufacturer of BOTOX advices that retreatment should not considered 
within 12 weeks from the prior bladder injection.[5, 11] Repeated injections of BTA into the 
detrusor muscle have not been found to cause inflammatory infiltration or fibrotic activity in 
the bladder wall.[25, 26] In treating adult patients for one or more indications, the maximum 
cumulative dose for BOTOX should not exceed 360U, in a 3 month interval [5, 11]
Conclusions: 
BTA treatment is an easy to learn frequently used treatment in urology departments. But despite 
many urologists treat patients with BTA there is still a request for training in the practical and 
technical aspects to achieve the best clinical outcome. More research must be done to find 
which injections technique gives the best results, but the former theory that injection into 
the trigone will induce VUR has been depraved. No predictive value of performing an UDI 
prior to BTA treatment is found to allow preoperative stratifications. Retreatment should be 
considered when the clinical effect has waned but no sooner than 12 weeks from the prior 
detrusor injection. Repeated injections of BTA into the detrusor muscle have not been found 
to cause inflammatory infiltration or fibrotic activity in the bladder wall.
41 
Botulinum Toxin A in clinical practice, the technical aspects and what urologists want to know about it
C
h
ap
te
r 
3
Questionnaire:
1. Is BTA treatment used for OAB in your department?
a. Yes (96%)
b. No  (3%)
c. We are considering starting BTA treatment  (1%)
2. In which group of patients is BTA treatment used in your department? 
a. Neurogenic patients (3%)
b. Idiopathic patients (1%)
c. Both (96%)
3. Are there other departments in your hospital treating OAB with BTA?
a. Yes  (7%)
b. No (93%)
4. Who performs the BTA treatment in your department?
a. One urologist (28%)
b. Several urologists (58%)
c. All urologists (9%)
d. Residents, physician assistants and/or nurse practioners (2%)
e. All of the above (3%)
5. Is an UDI performed prior to BTA treatment?
a. Yes, only for the first treatment  (26%)
b. Yes, for the first treatment and after that on indication (57%)
c. Yes, before every treatment (4%)
d. No (13%)
6. Which type of cystoscope is used for BTA treatment?
a. Rigid cystoscope (53%)
b. Flexible cystoscope (13%)
c. Both, depending on the patients gender  (34%)
7. If extra training is requested, in which topic would this be useful? 
 (multiple answers possible)
a. Indication for the treatment; patient selection and exclusion  (73%)
b. Pathophysiology (38%)
c. Results of clinical studies (58%)
d. Guidelines: the place for BTA treatment compared to other 
e. treatment modalities (63%)
f. Practical aspect of BTA treatment and follow up (60%)
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8.  If extra training in the practical aspect is requested for BTA treatment, what should be 
trained? (multiple answers possible)
a. Preparing the BTA mixture (29%)
b. Application technique (where and how many injections)  (55%)
c. Necessary materials for the procedure (23%)
d. Cystoscopic aspects (31%)
e. Anesthesia and pain management (71%)
f. Treatment schedule (first treatment, sequent treatment, repeated treatment) (64%) 
g. Management retention and CIC (36%)
h. Management of UTI’s (40%)
9. What training form would have your preference? (multiple answers possible)
a. Theoretical training session (31%)
b. Proctor session (24%)
c. Workshop at the Dutch Urology meeting (67%)
d. Web-based e-learning (42%)
e. Paper /e-book with tips and tricks (46%)
f. Training during residency (31%)
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abstract 
Overactive bladder syndrome (OAB) symptoms and lower urinary tract dysfunction are often 
challenging to treat and have significant negative effect on the quality of life for many people. 
It lowers their self-esteem and health perception. The use of neuromodulation as a treatment 
has developed over the years and a lot of research has been done. This article will give an 
overview on neuromodulation treatment for OAB symptoms, including percutaneous tibial 
nerve stimulation (PTNS), sacral nerve stimulation (SNS), pudendal nerve stimulation (PNS), and 
dorsal genital nerve stimulation (DGNS). At this moment PTNS and SNS are widely adopted as 
a treatment with good results. PNS and DGNS stimulation seem to be promising for future use 
in clinical care. PTNS and SNS should be considered for treatment of OAB symptoms, especially 
in refractory OAB symptoms or when a patient experiences side effects of antimuscarinics. SNS 
therapy is more invasive and the costs are considerably higher, PNTS is less invasive and less 
expensive but more time consuming. The treatment modalities should be discussed with the 
patient and proper patient selection is mandatory. 
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1
Introduction 
The International Continence Society (ICS) and the International Urogynecological Association 
(IUGA) have defined overactive bladder syndrome (OAB) as urinary urgency, usually 
accompanied by frequency and nocturia, with or without urgency urinary incontinence in the 
absence of urinary tract infection or other obvious pathology [1]. Symptoms of lower urinary 
tract dysfunction are often challenging to treat and have significant negative effect on the 
quality of life for many people, it lowers their self-esteem and health perception and are very 
expensive [2, 3]. An estimated 455 million people worldwide (10.7%) experienced at least 1 
OAB symptom in 2008, with the worldwide prevalence is expected to increase to 500 million 
in 2013 and 546 million in 2018 [4]. In America approximately 34 million inhabitants have OAB 
[5] with associated costs exceeding $9 billion per year including direct care, health related 
consequences and lost productivity [6]. 
Conservative treatment, such as behavioral interventions and antimuscarinic drugs, does 
not always give sufficient improvement and/or are associated with considerable side effects 
such as dry mouth, blurred vision, constipation, erythema, fatigue and urinary retention [7, 8] 
resulting in terminating the treatment in 70% of the patients within 6 months [9-11]. In case 
of conservative treatment failure, neuromodulation as well as botulinum toxin A injections 
can be offered to the patient. The purpose of neuromodulation for the treatment of OAB is to 
target the innervation system that control the pelvic floor organs and specifically the lower 
urinary tract. This article will give an overview of neuromodulation treatment options after 
conservative treatment has failed. It will first concentrate on neuromodulation treatments used 
in clinical practice: percutaneous tibial nerve stimulation (PTNS), the least invasive followed 
by sacral nerve stimulation (SNS). Finally two experimental neuromodulation treatments, 
the pudendal nerve stimulation (PNS) and dorsal genital nerve stimulation (DGNS), will be 
discussed. 
Neuromodulation Treatments
Percutaneous Tibial Nerve Stimulation 
PTNS is an easily administrated procedure that can be done in the outpatient setting. The 
Urgent® PC is an FDA approved minimal invasive office based neuromodulation system. It is 
thought to deliver retrograde neuromodulation through the tibial nerve to the sacral nerve 
plexus via a percutaneous 34-gauge needle electrode. The most common protocol is the 
application of 30 min of stimulation once a week for 12 weeks. In order to keep benefitting 
from the treatment responders have to continue their treatment[12]. On the long term the 
optimal interval between stimulation sessions varies per person between 1-3 times a month, 
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with an average of once a month [13].   
Several articles have been published about PTNS treatment recently. The OrBit trial compared 
PTNS versus extended-Release Tolterodine [14]. A total of 100 adults were randomized 1:1 
to PTNS treatments or to 4mg daily extended release Tolterodine. Voiding diaries and an 
overactive bladder questionnaire were completed at baseline and after 12 weeks of treatment 
to compare 24-hour voiding frequency, urinary urge incontinence episodes, voids causing 
waking, volume voided, urgency episodes and quality of life indices. It showed a statistical 
significant subjective cure or improvement of 80% of the subjects in the PTNS arm, compared 
to 55% in the Tolterodine arm. The objective effectiveness was similar between groups. 
Improvement in all OAB symptoms episodes was statistically significant within each group 
from baseline to 12 weeks, but did not reach statistical significance compared between 
groups. Improvement in voids a day was seen in 73% of patients in the PTNS group versus 
74% of patients in the Tolterodine group. For Nocturia this was seen in 70% respectively 61%, 
for Urge incontinence in 80% versus 73%, for moderate to severe urgency episodes in 71% 
versus 75% and the voided volume showed improvement in 75% of subjects in the PTNS 
group versus 65% of subjects in the Tolterodine group.
The SUmiT trial comparing the result of 12 weeks of PTNS treatment to sham treatment 
220 adults were randomized 1:1. Primary end point was a moderately or markedly reported 
improvement of bladder symptoms after 13 weeks of treatment. OAB and quality of life 
questionnaires and 3-day voiding diaries were completed at baseline and at 13 weeks. 
Subject global response assessments (GRA) were completed at week 13. This trial described 
a significant improvement of bladder symptoms with 55% of subjects reported a moderately 
or markedly improved response in the PTNS group, compared to 21% in the sham group[15]. 
Patients voiding diaries parameters had significantly improvements in frequency, nocturia, 
voids with moderate to severe urgency, and urgency incontinence episodes compared to 
sham. There was also a significant improvement on the condition specific OAB-q symptoms 
severity score and the quality of life scores.
In the STEP study, an extension study of the SumiT trial, 50 from the 60 adults who met the 
primary end point in the SUmiT trial enrolled. The primary end point of the STEP study was 
a moderately or markedly reported improvement of bladder symptoms after 36 months. 
Patients received PTNS treatment in a tapering protocol followed by a personalized treatment 
plan. Twenty-nine subjects completed the protocol, of them 28 (97%) met the primary end 
point. A last value carried forward approach under intention to treat principle (LVCF-ITT) 
and a Bayesian model concluded a 76% respectively 77% had a subjective improvement of 
a moderate or marked result. All voiding parameters and the quality of life scores improved 
significantly. The average treatment frequency was once a month [13].
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Several reviews were published about PTNS treatment in the past years [16-18]. Describing 
success rates between 37%-93%. None of these articles or the articles discussed above 
describe serious treatment related adverse events. Unfortunately except the 3 year follow up 
in the STEP study little is written about the long term effect of PTNS treatment.
Although PTNS seems to be an effective treatment for OAB it is time-consuming for both the 
patient and the care-giver. The patient has to travel to the hospital and stay there for at least 30 
minutes and the care-giver has to perform the needle placement. A possible future solution 
to this can be the Urgent SQTM implant. The Urgent SQTM is an implant that is surgically placed 
near the posterior tibial nerve (PTN) and activated by an external pulse generator, allowing for 
on demand PTN stimulation outside the hospital, without the need for needle insertion. The 
follow up after implant driven PTN stimulation was first published by van der Pal in 2006 [19]. 
The device was inserted in 8 patients who previous had been successfully treated with PTNS 
(≥ 50% reduction of the number of incontinence episodes and/or voids on bladder diary). 
No complications from the surgical procedure were described. One year after implantation 
5 patients had significant improved voiding diary parameters and 4 of them had ≥ 50% 
reduction of the number of incontinence episodes and/or voids on bladder diary. Recently a 
9 years follow up for the Urgent SQ-implant is published by Janssen et al [20]. Seven patients 
still had the implant. Of the 4 patients who were successfully treated 1 year after implantation 
3 still used the device. No skin abnormalities, no walking difficulties, no soft tissue or bony 
abnormalities and no dislocation or migration of the implant was found. Despite of the small 
sample size of this study it may suggest that there could be a long term benefit for PTNS. 
Still further research is necessary, but this implant may be a solution to the time-consuming 
element of PTNS treatment for both the physician and the patient.
Sacral nerve stimulation
Sacral nerve stimulation (SNS) is approved by the USA Food and Drug Administration for 
three indications; urinary urgency incontinence, urgency-frequency syndrome, and voiding 
difficulties (incomplete and complete retention) [21]. The precise mode of action of SNS is 
unknown. There are at least two presumed mechanism of action: The first one claims that 
activation of efferent nerve fibers to the striated urethral sphincter reflexively causes detrusor 
relaxation [22]. The second presumed mechanism states that activation of afferent nerve fibers 
causes inhibition of the voiding reflex at a spinal and/or supraspinal level; pudendal nerve 
afferents seem to be particularly important for the inhibitory effect on the voiding reflex [23].
The procedure can be preceded by a preliminary test phase referred to as a percutaneous 
nerve evaluation (PNE). This test uses a non-anchored test-lead placed in the S3 foramen and 
connected to an external stimulator. The test extends between 4 and 14 days, after which the 
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lead is removed. Success of this test phase is generally defined as improvement of at least one 
major voiding symptom by more than 50%. The overall response rate for PNE is around 55%. 
Lead migration is considered the main factor of false negative results [24]. A true negative 
response to PNE of about 20% can be explained because the pudendal nerve afferents seem 
to be particularly important for the inhibitory effect on the voiding reflex and those afferents 
are confined to the S2 level only in 18% of all subjects [25, 26].
SNS is often preformed in a two stage-technique with a quadripolar lead with self-anchoring 
tines, first described by Spinelli et al in 2003 [27]. This technique enables test-stimulation to 
be performed using the permanent anchored lead that reduces the risk of migration. This 
lead is usually placed through the back skin in the S3 foramen at sacral level and tunnelled 
subcutaneously, where it is connected to a temporary extension lead that exits the body and 
is connected to an external test stimulator. This test period mostly extends to 3-4 weeks. If the 
voiding symptoms improve by more than 50%, the subject might undergo surgery to implant 
the internal pulse generator (IPG). 
Leong et al [28], compared the patients response rate to PNE versus 1st stage tined lead 
procedure. Eighty-two patients, comprising 69 OAB patients, were screened with both PNE 
and with a 1st stage tined lead procedure. More than 50% improvement in at least two relevant 
urinary symptoms was considered a positive response. The positive response rate on PNE was 
47% while 1st stage tined lead showed a 69% positive response rate. All patients with a positive 
1st stage tined lead received SNS treatment. Failure rate after 2 years was 2.9%. This study may 
suggest that 1st stage tined lead is a more sensitive screening rate method for SNS therapy. 
Long term data about the success rates of SNS are scarce. Van Kerrebroeck et al [29], published 
a prospective multicentre trial evaluating the long-term safety and efficacy of SNS in patients 
with refractory urge incontinence, urgency-frequency and retention. A total of 17 centers 
worldwide enrolled 163 patients for test-stimulation, of whom 152 patients received the 
implantation using Interstim. Voiding diaries were collected annually and clinical success was 
defined as ≥ 50% improvement from baseline in primary voiding diary variables. After five 
years 105 patients completed the follow up and of them 87 completed the voiding diary. 
Sixty-eight % of patients with urge incontinence, 56% with urgency-frequency and 71% with 
retention had successful outcomes.
Groen et al [30], published the 5 year results of SNS in 60 women with refractory idiopathic 
urge urinary incontinence. A non-tined lead procedure was used and success was defined 
as at least a 50% decrease in the number of incontinence episodes or pads used daily. At 5 
year SNS was still used in 48 (80%) patients of which 31 completed the voiding diaries. The 
success rate, patients with at least a 50% decrease in the number of incontinence episodes or 
pads used daily, gradually decreased from 52 patients (87%) at 1 month to 37 (62%) at 5 years. 
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Complete continence persisted in 15% of patients. 
As with all treatments adverse events in SNS therapy are described [31, 32], this mainly 
encompassed pain, infection, bowel dysfunction and change in clinical effect often due to 
lead migration. Based on the summarized adverse event data, many wound complications and 
some changes in efficiency can be managed conservatively without repeat surgery. Published 
rates of infection range from 0% to 11% in various studies [33]. Rates of surgical revision and 
explantations vary in literature. 
There is a decline in therapy effect of SNS over the years. If patients are successfully treated 
with SNS the battery will eventually empty and a surgical intervention to change the battery 
will be necessary. The typical battery life is 8–10 years; depending on the parameters used 
for stimulation. The expected lifespan of ‘‘Interstim II’’ lies around 3–5 years when used 24 
hr/day. There is also a percentage of patients treated with SNS who, after a few years, don’t 
benefit from their therapy despite of adequate nerve stimulation. A suggested hypothesis for 
this phenomenon is habituation of the nerve system to prolonged stimulation of the sacral 
nerves[34]. 
If on demand stimulation would be possible it will lead to a longer battery life and it may 
decrease the risk of adaptation of the nervous system. To answer this question, Oerlemans 
et al [35] completed a pilot intervention study for on-demand SNS in patients with urge 
incontinence and urgency-frequency syndrome. Twenty-one patients participated of which 
5 were randomized into a control group (continuous stimulation) and 16 into the on-demand 
group. The on demand group was asked to switch the device off, and on again when they felt 
recurrent symptoms. Of the study group, 10 patients reported no worsening of the symptoms 
by on demand nerve stimulation. The mean off-time was 12.4 hours. The other six had 
worsening of their symptoms. Larger randomized studies with longer follow- up are needed, 
but this pilot study suggests that in the majority of patients on demand SNS treatment could 
be possible, implying less battery changes and therefore lower therapy costs. If on demand 
stimulation reduces the decline in therapy effect over the years due to adaptation of the 
nervous system it could give better long term results. 
Costs
There are several publications about the cost effectiveness of the treatment for OAB, in 
particular for PTNS and SNS. Various articles show different costs, since the medical care systems 
differ between countries. Leong et al [36], published that the cost of SNS as a treatment for 
OAB syndrome in the Netherlands is $15.743 over a 2 year time period. D’Ausilio et al [37], 
calculated the 10 years cost for SNS in Italy at €33.897. Staskin et al [38], compared the costs of 
PTNS to SNS for OAB syndrome in the USA. PTNS is the least costly with $7.565 for a three year 
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treatment, compared to SNS which costs $24.681 for the same treatment period. Chen et al 
[39], calculated that one year treatment for PTNS costs $4.375 per patient. Martinson et al [40] 
also concludes that PTNS had substantially lower costs compared to SNS in the US of America. 
Although it’s difficult to compare between countries the treatment costs for SNS are higher 
compared to PTNS treatment.
Apart from PTNS and SNS, two promising neuromodulation treatments nowadays are used in 
experimental settings: pudendal neuromodulation (PNS) and dorsal genital nerve stimulation 
(DGNS).
Pudendal nerve stimulation 
The pudendal nerve (PN) originates from the S2, S3, and S4 sacral nerve root. It is a somatic 
nerve and innervates the external genitalia as well as both the external urethral sphincter (EUS) 
and the external anal sphincter (EAS). The main trunk passes over the ischial spine and enters 
Alcock’s canal. Selection of the PN, as a site of stimulation, provides afferent stimulation of S2, 
S3, and S4. The PN has three major branches, the inferior rectal nerve, the dorsal genital nerve 
(DGN) and the perineal nerve, with a high variation in branching patterns. Afferent PNS has 
been demonstrated to inhibit the micturition reflex, abolish uninhibited detrusor contractions, 
and increase bladder capacity in animals and humans[41, 42]. The potential advantage of PNS 
compared to SNS is increased afferent neuromodulation. Different approaches for electrical 
stimulation of the PN that were described by Martens et al [43]. The posterior approach using 
the ischial spine as a landmark, can be approached by inserting a wire electrode perpendicular 
at the intersection of a horizontal line from the greater trochantor and a vertical line from the 
ischial tuberosity tip. With the perineum approach the electrode is inserted perpendicularly to 
the perineum between the ischial tuberosity and the anus. 
The use of chronic pudendal nerve stimulation (CPNS) in refractory neurogenic urgency 
incontinence with a minimal invasive procedure was first reported by Spinelli et al [44] in 
2005. Fifteen patients underwent CPNS, 6 with the perineal approach and 9 with the posterior 
approach. Eight patients became continent, 2 improved by more than 88% and 2 reduced 
the number of incontinence episodes by 50%. In the 12 patients with a response of ≥ 50% 
improvement of urgency incontinence episodes an implantable pulse generator (IPG) was 
implanted. At an average follow-up of 6 months these patients with the implanted IPG 
perceived the same clinical efficacy as achieved during the screening phase.
In 2005 a prospective randomized single-blind, cross-over trial of SNS versus PNS was reported 
by Peters et al [45], including patients with urgency-frequency, urgency incontinence, and 
non-obstructive urinary retention. Thirty subjects were implanted with a tined lead at S3 and 
a second electrode implanted at the PN by the perineum approach. In a blinded, randomized 
fashion, each lead was tested for 7 days. An overall 50% improvement was considered as a 
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positive response. Twenty four patients responded to nerve stimulation. Of these, PNS gave 
overall improvement in symptoms of 63%, whereas those with SNS reported an overall 
improvement of 46%. Of patients whose symptoms improved more than 50%, 79% desired to 
have PNS compared to 21% for SNS. On the GRA scale PNS was superior to SNS for pelvic pain, 
urgency, frequency and bowel function. There was no significant difference in voiding diary 
parameters. 
Continuous or conditionally stimulation can be applied. Continuous stimulation produces 
stimuli constantly. In conditional stimulation, stimulation takes place when a certain 
condition, like an involuntary detrusor contraction (IDC), occurs. Conditional stimulation is 
most likely at least as effective as continuous stimulation to increase bladder capacity, but 
reduces stimulation time. This can lengthen battery lifespan and might prevent habituation 
to stimulation. Unfortunately there is not yet a reliable independent warning signal for IDC 
but patient controlled stimulation can be applied. The clinical benefit of patient controlled 
stimulation has to be studied in future chronic clinical studies [43].
The literature about PNS for OAB is encouraging but limited and indicates that PNS might 
be a reasonable option for OAB in the future when more successful long-term clinical results 
become available. 
Dorsal Genital Nerve stimulation
The DGN, being the dorsal penile nerve (DPN) or the dorsal clitoral nerve (DCN), is a branche of 
the PN. After leaving the Alcock’s canal anteriorly the DGN continues cranially where it contacts 
the inferior ramus of the pubis and subsequently courses to the inferior border and anterior 
surface of the body of the pubis. In the male the nerve courses proximal to the insertion of 
the cavernous body, and continues between the cavernous body and the anterior surface 
of the pubis to the dorsum of the penis. The nerve divides and runs bilaterally on the dorsal 
side to the penis between the tunica albuginea and Buck’s fascia to terminate in the penile 
gland. In the female the nerve travels form the anterior surface of the body of the pubis then 
piercing the perineal membrane lateral to the external urethral meatus. It traversed along the 
bulbospongiosus muscle before traversing posteriorly to the crura. The nerve hooks over the 
crura to lie on the anterolateral surface of the body of the clitoris, before dividing into two 
cords and terminating short of the tip of the clitoral gland [43, 46]. The DGN is more superficial 
and therefore perhaps more suited for less invasive stimulation techniques. The mechanism of 
action of DGNS is thought to be by afferent stimulation of the PN. DGNS is not yet used in daily 
clinical practice. All publications so far are done in research settings.
Goldman et al [47], performed DGNS in 21 patient with non neurogenic OAB using a 
percutaneously placed electrode. “Improvement” was defined as a ≥ 50% reduction in each 
of the measured incontinence parameters: 24hr pad test weight, incontinence episodes a day, 
pads per day (PPD) and the amount of severe urgency episodes. Nineteen of the 21 subjects 
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completed the week of stimulation. In two subjects the electrode failed, one broke and one 
dislodged. Of the 19 who completed the home stimulation week, fifteen (79%) subjects 
reported a reduction in incontinence episodes and nine (47%) experienced a ≥ 50% reduction 
in the number of incontinence episodes. Of those nine the mean reduction of incontinence 
episodes a day was 89%. Eight of the 17 (47%) reporting on PPD had a ≥ 50% reduction and 
thirteen (76%) of the 17 subjects who performed a 24h pad-test had a ≥ 50% reduction in 
pad weight and 8 (47%) were complete dry. Thirteen (68%) from the 19 had ≥ 50% reduction 
in severe urgency episodes with an average reduction of 82%. Seven patients experienced 
side effects, ranging from skin irritation to pain and bruising around the electrode exit site. All 
were mild and recovered spontaneously within 11 days of the implant procedure. This study 
is the first to demonstrate the feasibility of DGN stimulation via a percutaneous electrode for 
treatment of urge-incontinence in the non neurogenic population. The results for DGNS in 
this study are comparable to the improvements seen with SNS. This finding is encouraging 
to perform further studies to investigate whether DGNS is a reasonable treatment option for 
OAB.
Most of the publications about DGNS are performed with patients with neurogenic detrusor 
overactivity (NDO). In those studies good results concerning bladder capacity, suppression 
of IDC are reported. Martens et al [48], performed DGNS with an needle electrode in 8 SCI 
patients with DO, and reported a success rate of 100% in suppression of one or more IDC with 
conditional stimulation in neurogenic patients. Opisso et al [49], compared patient controlled 
versus automatic stimulation with surface electrodes in 17 patients with NDO and reported 
that patient controlled DGNS is as effective as automatic controlled stimulation to treat NDO. 
The above studies for DGNS in neurogenic patients are studies with short term DGNS in a 
clinical setting. Recently Opisso et al [50], published a study with subject controlled DGNS in 11 
patients with NDO and urgency incontinence at home during 3 days. In this study DGNS was 
provided with surface electrodes placed either on the dorsal of the penis in males and on or 
close to the clitoris in females. Eight subjects completed the protocol containing a cystometry 
on day 1 and day 5 and at home subject controlled DGNS on day 3,4 and 5. The bladder diary 
showed a significant higher mean voided volume at day 2,3, 4 and 5 compared to day 1. None 
of the subjects reported an incontinence episode on day 4 and 5. This study demonstrates 
that DGNS in patients with intact bladder sensation is a feasible and promising technique to 
increase bladder capacity but also suggests a carry-over effect.
In 2012 Farag et al [51], conducted a review about DGNS. This review contained 17 articles 
of studies applying DGNS through either surface electrodes, wire electrodes or needle 
electrodes. It concluded that chronic DGNS seems to be of value in the management of OAB.
Although the number of patients studied with DGNS in OAB is small, the results of the 
publications mentioned above look promising for DGNS in both continuous and conditional 
stimulation.
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Conclusion: 
Neuromodulation is a proven treatment for OAB symptoms. At this moment PTNS and SNS 
are widely adopted as a treatment with good results. They are both indicated for treatment of 
refractory OAB symptoms. SNS therapy is more invasive and the costs are considerably higher, 
PNTS is less invasive and less expensive but more time consuming. The treatment modalities 
should be discussed with the patient and proper patient selection is mandatory. Experimental 
treatments like PNS and DGNS are promising but more research is needed before these 
modalities can be offered in clinical practice. 
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CHAPTER 4.2
Introduction
Neuromodulation of the lower urinary tract is extensively applied in patients with Overactive 
Bladder (OAB) complaints. The best known and best documented technique is sacral nerve 
stimulation (SNS). Posterior or percutaneous tibial nerve stimulation (PTNS) is the second most 
extensively documented way of nerve stimulation. The exploration of the best technique of 
electrical stimulation of the lower urinary, including sex organs, is guided by three principles: 
1 Stimulation should be done via the least invasive way. 
  For this reason transcutaneous stimulation with surface electrodes or stimulation probes 
would suit best. 
2  Stimulation should be in an area that is acceptable and not embarrassing for patients. 
 This makes sacral dermatomes or legs appropriate areas for stimulation. 
3 Stimulation should be practical to apply. 
  Continuous stimulation is therefore less ideal and discontinuous stimulation is easier than 
continuous stimulation.
Ways of peripheral neuromodulation
The nerves that innervate the lower urinary tract originate from the lumbar, sacral and 
coccygeal segmental nerves from L2 to S4 (figure 1). Afferent and efferent fibers from these 
segmental sacral roots merge in the periphery outside the spinal cord. After merging the 
nerve fibers continue as combined nerves that have lost their segmental innervation pattern. 
The sciatic nerve is composed of fibers from L4 to S3. The posterior tibial nerve is a part of 
the sciatic nerve. Peripheral neuromodulation of the lower urinary tract has been attempted 
via stimulation of those nerves that are related or involved in pelvic organ innervation. These 
are the pudendal nerve, the dorsal genital nerve and the posterior tibial nerve. Peripheral 
neuromodulation can also be done via the overlying skin or by stimulating the dermatomes 
that are innervated by the same nerve as the ones that innervate the lower urinary tract.    
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Figure 1: organisation of the lower lumbar, sacral and coccygeal nerve plexus, the merger of the various 
roots and the most important nerves that branches from the merged nerve plexus. The tibial nerve has 
it’s offspring in the sacral roots of mainly S2 and S3. 
This chapter describes the clinical practice and developments of the peripheral 
neuromodulation systems, in particular PTNS, pudendal nerve stimulation and dorsal genital 
nerve stimulation.
Posterior Tibial Nerve Stimulation
History 
It is an ancient Chinese custom to perform acupuncture of the lower leg. With this technique, 
developed in China over 5,000 years ago, the “energetic harmony” of the urogenital tract 
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might be restored by way of stimulation of specific points. Wilhelmus ten Rhyne (1647-1700) 
was a Dutch physician who was employed by the Dutch East India Company in 1673 were 
he encountered eastern traditional medicine (figure 2). In 1683 he published a book entitled 
“Dissertatio de Arthritide: Mantissa Schematica: De Acupunctura: Et Orationes Tres”. [1] He 
wrote about the art of needling for treating diseases including those of the lower urinary 
tract. He called this technique ‘Acupunctura’ and it was the first Western detailed study on that 
matter.
Figure 2: Wilhelmus ten Rhyne, the first Western physician to describe the ancient Chinese technique 
of acupuncture.
69 
Peripheral Neuromodulation
C
h
ap
te
r 
4.
2
One of the most commonly used acupuncture points used for gynaecological, fertility, 
digestive, urinary, sexual and emotional disorders is the sanYinJiao point, or Spleen 6 (fig 3). 
It can be translated as ‘Three Yin Intersection’, because it is the a meeting point of the three 
yin channels of the leg: Spleen, Liver and Kidney. SanYinJiao, SP-6 or Spleen 6 is located on 
the medial side of the lower leg, about 6-8 cm cephalad to the prominence of the medial 
malleolus. It lies close to the medial crest of the tibia. The location of the SP-6 acupuncture 
point and the organs affected by this kind of acupuncture has remarkable similarities with 
posterior tibial nerve stimulation. When electrical current is applied to the acupuncture 
needle the technique is called electrical acupuncture. Especially when electrical acupuncture 
is performed with similar stimulation parameters (2-15 Hz,10-20 mA) it is likely that nerve 
stimulation is the effective treatment. Similar effects as with tibial nerve stimulation therefore 
might be expected on the pelvic organs perhaps as well as on the spleen and on the liver. 
Figure 3. Schematic drawing of acupuncture points including the SP-6 location at the medial malleolus. 
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The fundamental feature of neuromodulation as compared to acupuncture is that nerves are 
stimulated and not energy pathways or other routes that do not have any anatomical substrate. 
Nerve stimulation ideally has a efferent motor effect and a afferent sensory effect. Stimulation 
of posterior tibial nerve results in great toe flexion or fanning of the toes. The sensory effect 
is a radiation tickling sensation of the foot sole. McGuire was the first to explore tibial nerve 
stimulation in 1983.[2] He performed transcutaneous posterior tibial nerve stimulation in 15 
patients with detrusor overactivity because of a neurological disease.
Inspired by this previous work by McGuire, Marshall Stoller started research on percutaneous 
tibial nerve stimulation as neuromodulative treatment in lower urinary tract dysfunction. After 
initial testing in pig-tailed monkeys, PTNS was later investigated in humans with promising 
results.[3] This new initiative was the start of the world-wide development and exploration of 
PTNS. 
Historic overview
5000 BC Acupuncture of lower leg in China
1683   Wilhelmus ten Rhyne writes Dissertatio de Arthritide: Mantissa Schematica: 
 De Acupunctura: Et Orationes Tres 
1983 McGuire performs transcutaneous posterior tibial nerve stimulation
1987 Percutaneous tibial nerve stimulation by Stoller
1999 Clinical introduction of PTNS
2006 First publication on tibial nerve implant by van der Pal
2009 First randomized controlled trial by Peters
Technique 
PTNS is performed in patients placed in the supine position with the medial malleolus 
pointing upwards. A 34 gauge stainless steel needle is inserted approximately 3 to 4 cm, about 
3 fingerbreadths cephalad to the medial malleolus, between the posterior margin of the tibia 
and soleus muscle. A stick-on electrode is placed on the same leg near the arch of the foot. 
The needle and electrode are connected to a low voltage (9 volts) stimulator (Urgent PC®, 
Uroplasty Inc, Minnetonka, MN) with an adjustable pulse intensity of 0 to 10 mA., a fixed pulse 
width of 200 microseconds and a frequency of 20 Hz (Fig 4). The amplitude is slowly increased 
until the large toe starts to curl or toes start to fan. If the large toe does not curl or pain occurs 
near the insertion site, the stimulation device is switched off and the procedure is repeated. If 
the large toe curls or toes start to fan stimulation is applied at an intensity well tolerated by the 
patient. If necessary the amplitude can be increased during the session. In general, patients 
undergo 12 outpatient treatment sessions, each lasting 30 minutes one to three times per 
week. If a good response occurs the patient is offered chronic treatment.[4]
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Figure 4. Technique of PTNS
Working mechanism
At the moment the working mechanism of neuromodulation, including PTNS, is still not 
completely understood. However, it is postulated that symptoms of OAB including incontinence 
may represent an alteration of the pelvic neuromuscular environment via changes in the 
inhibitory and excitatory signals of the voiding reflex. It is thought that electrical stimulation 
of the sacral nerve roots modulates the afferent neural reflex pathways between the spinal 
cord or pons and pelvic organs. As the ascending sensory pathway inputs and guarding reflex 
pathway are modulated, storage may be facilitated. 
Blok et al looked at the effects of acute and chronic sacral neurostimulation on PET images 
of the brain.[5] In the acute phase brain areas are involved that have to do with sensorimotor 
learning. These are the areas located in the right postcentral gyrus, the left parietal cortex, 
the medial prefrontal cortex and the right insula. Furthermore, there was activation in the 
ventromedial orbitofrontal cortex, and decreased activation in the left medial cerebellum.
However chronic SNS decreased activity in the cerebellum, midbrain and adjacent midline 
thalamus and limbic cortical areas, previously implicated in the control of micturition and 
urinary storage. They postulated that neuromodulation modulates predominantly areas 
involved in sensorimotor learning, which might become less active during the course of 
chronic SNS.
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In analogy to SNS central effects have been studied in PTNS. Finazzi Agro et al studied the effect 
of PTNS and sham stimulation on Short Latency somatosensory evoked potentials (SL-SEP) and 
long latency somatosensory evoked potentials (LL-SEP).[6] Somatosensory evoked potentials 
(SEP) reflect information processing in the brain after stimulation of peripheral somatosensory 
system. In particular, LL-SEP seem to provide information on the function of somatosensory 
associative cortical structures. LL-SEP changes imply that long time after stimulation (one day 
after treatment) changes in SEP occur. They showed that the amplitude of LL-SEP changes of 
P80 and P100 waves in the active PTNS group was significantly higher as compared to the 
placebo group. 
The recorded P80 and P100 amplitude increase might reflect long-term modifications in 
synaptic efficiency through the somatosensory pathway induced by repetitive peripheral 
nerve stimulation. Long-term potentiation (LTP) and depression (LTD) of excitatory synaptic 
transmission can contribute to experience-dependent modifications of brain function, 
including learning and memory. Thus, a plastic reorganization of cortical network triggered 
by peripheral neuromodulation can be hypothesized as a mechanism of action of PTNS. They 
concluded that PTNS effects are mediated by suprasacral centers of stimulus elaboration 
involving finally cortical associative areas. This is in line with the theories about the working 
mechanism of SNS.  
If one considers applying PTNS for improvement of clinical conditions one has to accept that:
•	 It is possible to positively influence the innervation system of the lower urinary tract by 
stimulation of the tibial nerve at the ankle
•	 There is no direct sensation in the bladder area nor motor action of muscles in or adjacent 
to the pelvic floor during tibial nerve stimulation
•	 Discontinuous stimulation during a limited period of time once to thrice a week is sufficient 
to have a beneficial affect 
Clinical Results
Since the introduction of PTNS in 1999 several studies have been performed evaluating its 
effectiveness in especially patients with OAB dry and OAB wet and non-obstructive urinary 
retention. 
Almost all studies on overactive bladder used micturition diaries and general and/or disease 
specific quality of life questionnaires to measure the effects of PTNS.[7, 8] Subjective success 
was found in 59-64% of patients. Objective success, defined most of the time as more than 
50% decrease in incontinence episodes and/or micturition frequency, was found in 47-56% of 
patients.[8, 9] 
Urodynamic studies especially measured by cystometry may provide more objective data 
on the efficacy of percutaneous tibial nerve stimulation. When acute PTNS is performed as 
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soon as detrusor overactivity (DO) is observed during cystometry the suppressive effects in 
neurological patients, are contradicting.[10, 11] 
Frequency/volume chart data and quality of life scores improved significantly. Of the 
participants with pre- and post-treatment urodynamic data, only a few showed complete 
abolishment of detrusor overactivity.[12] Nevertheless, increments in cystometric bladder 
capacity and in volume at occurrence of DO were significant. Subjects without detrusor 
overactivity at baseline appeared 1.7 times more prone to respond to PTNS. The more the 
bladder overactivity was pronounced, the less these patients were found to respond to PTNS. 
Once positive treatment outcome has been obtained with PTNS, a maintenance program is 
needed to avoid recurrence of complaints. One study evaluated the necessity of maintenance 
therapy by means of a 6 week pause of therapy in successfully treated PTNS patients, leading 
to over 50% worsening of main symptoms in almost all patients. Restarting PTNS afterwards 
improved complaints to the level present before the break in treatment.[13]
One of the most important studies on PTNS was performed by Peters et al.[14] The so called 
Study of UrgentPC versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms 
(SUmiT) was a multicenter, double-blind, randomized, controlled trial comparing the 
efficacy of percutaneous tibial nerve stimulation to sham through 12 weeks of therapy. The 
breakthrough was that a validated sham arm was developed and used as a comparator. This 
was the first time that the net effect apart from the placebo effect could be measured. In two 
groups of 110 patients the improvement in global response assessment (GRA), voiding diary 
parameters, and overactive bladder and quality of life questionnaires was evaluated. The GRA 
is a self-reported 7 point scale that tells whether an individual perceives a change due to the 
treatment. Individuals notes that a treatment who noted a moderate or marked improvement 
were regarded as successfully treated patients. Voiding diary parameters after 12 weeks of 
therapy showed percutaneous tibial nerve stimulation subjects had statistically significant 
improvements in frequency, night time voids, voids with moderate to severe urgency and 
urinary urge incontinence episodes compared to sham. The GRA in the PTNS subjects showed 
that 55% reporting moderately or markedly improved responses compared to 21% in the sham 
group. Another sham controlled study was performed by Finazzi et al with similar results. [15] 
PTNS implies that patients have to have repeat treatments. The tapering studies show that 
once every 2 or 3 weeks is sufficient in those patients that benefit from PTNS. Another major 
question is what the long term success of PTNS is. Peters et al followed 50 participants from 
the SUmiT Trial who met the primary effectiveness endpoint after 12-weekly PTNS.[16] These 
patients were prescribed a fixed-schedule 14-week tapering protocol followed by a personal 
treatment plan aimed at sustaining OAB symptom improvement. Of this group 29 patients 
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completed the 36-month protocol and received a median of 1.1 treatments per month. At 
three years 77% maintained moderate or marked improvement in OAB symptoms. Compared 
to baseline, median voids per day decreased from 12.0 to 8.7, and urge incontinence episodes 
per day decreased from 3.3 to 0.3. All quality of life parameters remained markedly improved 
from baseline through three years. 
•	 PTNS gives improves OAB symptoms based on voiding diary parameters in 47%-56%
•	 Subjective improvement is obtained in about 60% of patients
•	 PTNS increases cystometric capacity and delays the onset of, but does not abolishes 
detrusor overactivity. 
•	 Maintenance therapy is necessary to sustain the effect of therapy.
•	 PTNS improved bladder symptoms measured with GRA in 55% as compared to 21% in a 
sham treated group.
•	 After 3 years 77% of responding patients to initial therapy experienced moderate to 
marked improvement on OAB symptoms.  
Prognostic factors for PTNS
Little data are available abut prognostic factors for success of failure of PTNS. Studies on 
urodynamic changes by PTNS suggest that in case of overactive bladder, without detrusor 
overactivity, patients are more prone to a successful treatment outcome.[12] Clinical 
parameters for predicting SNS outcome were also tested in 132 patients treated with PTNS, 
but showed no significance.[17] Also a history of sexual and/or physical abuse did not alter 
PTNS treatment outcome. However, a low total score at baseline in the SF-36 general quality of 
life questionnaire proved to be predictive for not obtaining objective nor subjective success. 
Especially patients with a low SF-36 Mental Component Summary were prone to fail. These 
patients also scored worse on disease-specific quality of life questionnaires, although they had 
no different disease severity compared to patients with good mental health.
•	 Subjectives with mental problems don’t seem to be ideal candidates for PTNS
Urgent-SQ; the PTNS implant
Rather quickly after the modern clinical development of PTNS it was recognized that the 
repeated return to the clinic, once weekly or once bi- or triweekly, would finally lead to a 
logistic problem with patients returning to the clinic approximately 1-2 times per month. If all 
successfully treated patients would return every week this would lead to a jammed outpatient 
clinic. More importantly, the travel burden for patients would be high and PTNS-treatment-
on-demand would not be possible. Therefore an implant was developed that was placed at 
the tibial nerve at the ankle and that could be operated via radiofrequency activation with an 
external stimulator: the Urgent SQ (figure 5 ad figure 6). 
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Figure 5. The Urgent-SQ implant consisting of an internal electromagnetic pulse receiver, the body, 
with two leads, and monopolar platinum electrodes.
Figure 6. Site of implantation during surgery. The two electrodes are placed on two opposite sides of 
the tibial nerve just proximal to the medial malleolus.
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The pioneering work was done by van der Pal et al.[18] They looked at eight patients with 
refractory OAB who were treated with the Urgent-SQ. After implanting the device the patients 
could operate the implant by means of an external stimulator. Patients were evaluated at 3, 
6, and 12 months f follow-up. The primary objective was >= 50% reduction in the number 
of incontinence episodes and/or voids on bladder diary. At 3, 6 and 12 months, respectively 
five, six, and four patients met the primary objective. At 3- and 6- month follow-up, voiding 
and quality of life parameters had significantly improved. Urinary tract infection, temporarily 
walking difficulties, and spontaneous radiating sensations were reported as adverse events 
and no local infection, erosion, or dislocation.
Janssen et al reported about the long term efficacy and safety of these patients in an open-
label study.[19] The seven patients who still had the implant were contacted after 9 years and 
evaluated with an interview, physical examination, ankle X-ray, voiding diaries, and completed 
questionnaires about adverse events, performance, efficacy, safety, and quality of life with the 
validated I-QoL). Results showed that six of the seven patients still had sensory and loco-motor 
responses on stimulation at 9-year follow-up. Four patients who had a successful treatment 
response at 1 year, still used the device. The implants were intact with no migration and/or 
displacement. Two patients experienced minor discomfort. The conclusion was that after 9 
years the Urgent-SQ implant was a safe therapy for OAB. 
•	 A pilot study reveals that the Urgent SQ implant appears to be a safe and effective 
treatment for OAB 
Costs 
Several manuscripts have been published about the cost effectiveness of the treatment for 
OAB, in particular for PTNS and SNS. Various articles show different costs, since the medical 
care systems differ between countries. Leong published that the cost of SNS as a treatment for 
OAB syndrome in the Netherlands is $15.743 over a 2 year time period.[20]D’Ausilio calculated 
the 10 years cost for SNS in Italy at €33.897, whereas Staskin, compared the costs of PTNS 
to SNS for OAB syndrome in the USA.[21, 22] PTNS is the least costly with $7.565 for a three 
year treatment, compared to SNS which costs $24.681 for the same treatment period. Chen 
et al calculated that one year treatment for PTNS costs $4.375 per patient.[23] Martinson also 
concludes that PTNS had substantially lower costs compared to SNS in the US of America.[24] 
Although there is variation between countries is appears that PTNS is less costly compared to 
SNS. 
Future perspectives of PTNS
Percutaneous Tibial Nerve Stimulation is a minimally invasive, easily accessible neuromodulation 
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technique and has proven its benefit in overactive bladder and non- obstructive urinary 
retention. Regretfully, in chronic pelvic pain the effects seem to be only modest. At this 
moment quite some ‘circumstantial’ evidence exist for its efficacy, based on animal studies, 
clinical studies including urodynamic parameters. In case PTNS becomes a more established 
treatment modality, no doubt other indications will be explored. Subject for further 
investigation of areas that have already some clinical efficacy data are children, neurologic 
patients and patients with fecal incontinence. 
Almost all research done on PTNS used the same stimulation protocol: PTNS was performed 
in 10 to 12 weekly sessions, each lasting for 30 minutes. Stimulation parameters were pre-set 
and rather fixed and every time only one needle was inserted. It may be well anticipated 
that changes in treatment scheme and/or stimulation parameters could lead to a different, 
possibly even better outcome. The same goes for bilateral instead of unilateral therapy. It is 
evident that an accelerated stimulation scheme has the advantage of achieving clinical results 
faster.[25] Regarding stimulation parameters, it is rather widely agreed that pulse intensity in 
neuromodulation should be set at a well tolerable level. As it is suggested that frequency 
is optimal at more unpleasantly low levels (5-6 Hz), studies on PTNS with pulse frequencies 
below 20 Hz may produce better results.[26] The same goes for changes in pulse duration, in 
PTNS the standard setting is 0.2 msec. 
The recent revitalization of the Urgent-SQ create other possibilities. Efforts should be 
undertaken to refine the pre-implant testing phase in order to decrease the amount of 
unnecessarily treated patients. Hopefully this will eventually lead to the ideal implant: an 
effective and safe, easily controllable device that is operated by patients themselves in flexible, 
individualized treatment schemes. 
Apart from the clinically available and accepted PTNS and SNS treatments, two promising 
peripheral neuromodulation possibilities nowadays are used in experimental settings: 
pudendal nerve stimulation and dorsal genital nerve stimulation. 
Pudendal nerve stimulation 
The pudendal nerve (PN) originates from the S2, S3, and S4 sacral nerve root. It is a somatic 
nerve and innervates the external genitalia as well as both the external urethral sphincter 
(EUS) and the external anal sphincter (EAS). The main trunk passes over the ischial spine and 
enters Alcock’s canal. Selection of the PN, as a site of stimulation, provides afferent stimulation 
of S2, S3, and S4. The PN has three major branches, the inferior rectal nerve, the dorsal genital 
nerve (DGN) and the perineal nerve, with a high variation in branching patterns. Afferent PN 
stimulation has been demonstrated to inhibit the micturition reflex, to abolish uninhibited 
detrusor contractions, and to increase bladder capacity in animals and humans.[26, 27] The 
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potential advantage of PN stimulation compared to SNS is that PN stimulation recruits more 
afferent fibers. Since the presumed main working mechanism of all types of neuromodulation 
is in afferent direction, the recruitment of as many afferent fibers as possible therefore makes 
sense. Different approaches for electrical stimulation of the PN were described by Martens as 
is depicted in figure 7.[28]
Figure 7. Approaches for electrical stimulation of the pudendal nerve and dorsal nerve of the penis or 
clitoris. The PN originates primarily from the second, third and fourth sacral nerve roots, and it sometimes 
gains contributions from the adjacent roots of S1 and S5. The PN can be accessed for stimulation at the 
ischial spine by a posterior (A) or perineum approach (B) for insertion of an electrode. With a perineum 
approach the PN can also be reached at Alcock’s canal (C). The DGN can be stimulated using surface 
electrodes or percutaneously implanted electrodes (D).
The posterior approach using the ischial spine as a landmark, can be accessed by inserting a 
wire electrode perpendicular at the intersection of a horizontal line from the greater trochanter 
with a vertical line from the ischial tuberosity tip. When one wants to approach the pudendal 
nerve form the perineum the electrode is inserted perpendicularly to the perineum between 
the ischial tuberosity and anus. 
The use of chronic pudendal nerve stimulation in refractory neurogenic urgency incontinence 
with a minimal invasive procedure was first reported by Spinelli in 2005.[29] Fifteen patients 
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underwent chronic PN stimulation, 6 with a perineal approach and 9 with a posterior approach. 
Eight patients became continent, 2 improved by more than 88% and 2 reduced the number of 
incontinence episodes by 50%. In 12 patients with a response of >50% improvement of urge 
incontinence episodes an implantable pulse generator (IPG) was implanted. At an average 
follow-up of 6 months these patients with the implanted IPG perceived the same clinical 
efficacy as achieved during the screening phase. In the same year a prospective randomized 
single-blind, cross-over trial of SNS versus PN stimulation was reported by Peters, including 
patients with urgency-frequency, urgency incontinence, and non-obstructive urinary 
retention.[30] Thirty subjects were implanted with a tined lead at S3 and a second electrode 
implanted at the PN by the perineum approach. In a blinded, randomized fashion, each lead 
was tested for 7 days. An overall 50% improvement was considered as a positive response. 
Twenty four patients responded to nerve stimulation. Of these, PN stimulation gave overall 
improvement in symptoms of 63%, whereas those with SNS reported an overall improvement 
of 46%. Of patients whose symptoms improved more than 50%, 79% desired to have PN 
stimulation compared to 21% for SNS. On the GRA scale PN stimulation was superior to SNS for 
pelvic pain, urgency, frequency and bowel function. No difference in voiding diary parameters 
was observed. 
Continuous or conditionally stimulation can be applied. Continuous stimulation produces 
stimuli constantly. With conditional stimulation, stimulation takes place when a certain 
condition occurs, like an involuntary detrusor contraction (IDC), occurs. Conditional stimulation 
is considered as effective as continuous stimulation to increase bladder capacity, but it reduces 
stimulation time. This can lengthen the lifespan of an implanted battery and might prevent 
habituation to stimulation. Unfortunately there is not yet a reliable autonomous warning signal 
for IDC that can be used as a trigger for the stimulation action. So far only patient controlled 
stimulation can be applied. The clinical benefit of patient controlled stimulation has to be 
studied in future chronic clinical studies.[28]
The literature on PNS for OAB is encouraging but limited and indicates that PNS might be 
a reasonable option for OAB in the future when more successful long-term clinical results 
become available. 
•	 Pudendal nerve stimulation still is experimental but has conceptual advantages over other 
types of neuromodulation
•	 Few clinical studies exist that show at least a comparable clinical result as sacral nerve 
stimulation
•	 Broad clinical application and long term data are awaited for 
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Dorsal Genital Nerve stimulation 
The DGN, being either the dorsal penile nerve (DPN) or the dorsal clitoral nerve (DCN), is 
a branch of the PN. After exiting the Alcock’s canal anteriorly the DGN continues cranially 
where it contacts the inferior ramus of the pubis and subsequently courses to the inferior 
border and anterior surface of the body of the pubis. In the male the nerve courses proximal 
to the insertion of the cavernous body, and continues between the cavernous body and the 
anterior surface of the pubis to the dorsum of the penis. The nerve divides and runs bilaterally 
on the dorsal side to the penis between the tunica albuginea and Buck’s fascia to terminate 
in the penile gland. In the female the nerve travels form the anterior surface of the body 
of the pubis then piercing the perineal membrane lateral to the external urethral meatus. It 
traversed along the bulbospongiosus muscle before traversing posteriorly to the crura. The 
nerve hooks over the crura to lie on the anterolateral surface of the body of the clitoris, before 
dividing into two cords and terminating short of the tip of the clitoral gland.[28, 31] The DGN 
is running more superficial and therefore perhaps more suited for less invasive stimulation 
techniques. The mechanism of action of DGNS is thought to be by afferent stimulation of 
the PN. DGN stimulation is not yet used in daily clinical practice. All publications so far are 
about experiments in a research settings. Goldman performed DGN stimulation in 21 patient 
with non- neurogenic OAB using a percutaneously placed electrode.[32] Improvement was 
defined as a > 50% reduction in each of the measured incontinence parameters: 24hr pad 
test weight, incontinence episodes a day, pads per day and the amount of severe urgency 
episodes. Nineteen of the 21 subjects completed the week of stimulation. In two subjects 
the electrode failed, one broke and one dislodged. Of the 19 who completed the home 
stimulation week, fifteen (79%) subjects reported a reduction in incontinence episodes and 
nine (47%) experienced a > 50% reduction in the number of incontinence episodes. Of those 
nine the mean reduction of incontinence episodes a day was 89%. Eight of the 17 (47%) used 
less than 50% pads per day whereas 13 (76%) of the 17 subjects who performed a 24h pad-
test had a > 50% reduction in pad weight. Eight subjects (47%) were complete dry. Thirteen 
(68%) had > 50% reduction in severe urgency episodes with an average reduction of 82%. 
With regards to side effects 7 patients experienced side effects, ranging from skin irritation to 
pain and bruising around the electrode exit site. All were mild and recovered spontaneously 
within 11 days of the implant procedure. This study is the first to demonstrate the feasibility 
of DGN stimulation via a percutaneous electrode for treatment of urge-incontinence in the 
non-neurogenic population. The results for DGN stimulation in this study are encouraging and 
seem to be comparable to results of other ways of neuromodulation. 
Most of the publications about DGN stimulation are performed with patients with neurogenic 
detrusor overactivity (NDO). In those studies good results concerning bladder capacity, 
suppression of IDC are reported. Martens et al performed DGNS with an needle electrode in 8 
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SCI patients with DO, and reported a success rate of 100% in suppression of one or more IDC 
with conditional stimulation in neurogenic patients.[33] Opisso compared patient controlled 
versus automatic stimulation with surface electrodes in 17 patients with NDO and reported 
that patient controlled DGN stimulation is as effective as automatic controlled stimulation to 
treat NDO.[34]
The above studies for DGN stimulation in neurogenic patients are studies with short term 
DGN stimulation in a clinical setting. Recently Opisso reported about a study with subject 
controlled DGN stimulation in 11 patients with NDO and urge incontinence at home during 3 
days.[35] DGN stimulation was provided with surface electrodes placed either on the dorsal 
of the penis in males and on or close to the clitoris in females. Eight subjects completed the 
protocol. Higher bladder volumes with stimulation were seen. None of the subjects reported 
incontinence episodes on day 4 and 5. This study demonstrated that DGN stimulation in 
patients with intact bladder sensation is feasible and also suggested a carry-over effect. 
•	 Dorsal genital nerve stimulation is in concept an idea way of neuromodulation since it 
stimulates afferent nerve fibers
•	 All studies are still done in a research setting in mostly neurogenic patients
•	 Only short time data exist with promising clinical results   
Conclusions
Peripheral neuromodulation is a proven and accepted treatment for OAB symptoms. PTNS is 
minimally invasive and not very expensive but it is time consuming. Therefore new techniques 
with implants are explored. Experimental treatments like PN stimulation and DGN stimulation 
are promising but they are still in an experimental phase and the clinical applicability still is 
limited. 
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Sacral neuromodulation
Introduction 
The International Continence Society (ICS) and the International Urogynecological Association 
(IUGA) have defined overactive bladder syndrome (OAB) as urinary urgency, usually 
accompanied by frequency and nocturia, with or without urgency urinary incontinence in the 
absence of urinary tract infection or other obvious pathology. [1] Symptoms of lower urinary 
tract dysfunction are often challenging to treat and have significant negative effect on the 
quality of life for many people, it lowers their self-esteem and health perception and are very 
expensive. [2, 3] An estimated 455 million people worldwide (10.7%) experienced at least 1 
OAB symptom in 2008, with the worldwide prevalence is expected to increase to 500 million 
in 2013 and 546 million in 2018. [4] In America approximately 34 million inhabitants have OAB 
[5] with associated costs exceeding $9 billion per year including direct care, health related 
consequences and lost productivity. [6]
Conservative treatment, such as behavioral interventions and antimuscarinic drugs, does 
not always give sufficient improvement and/or are associated with considerable side effects 
such as dry mouth, blurred vision, constipation, erythema, fatigue and urinary retention [7, 8] 
resulting in terminating the treatment in 70% of the patients within 6 months. [9-11] In case of 
conservative treatment failure, sacral nerve stimulation (SNS) (Interstim®), percutaneous tibial 
nerve stimulation (PTNS) (Urgent®PC), and onabotulinum toxin A (BTA) (Botox®) are all FDA-
approved for treatment of refractory OAB. The purpose of neuromodulation for the treatment 
of OAB is to target the innervation system that control the pelvic floor organs and specifically 
the lower urinary tract. This chapter will discuss SNS treatment in clinical practice for OAB 
symptoms. 
Historical overview SNS therapy
The history of electrical stimulation in the urology field started in 1864 when Budge observed 
detrusor contraction in animals when stimulating the sacral spinal cord. In 1954, Boyd suggested 
a technique for direct electrical stimulation of the bladder in humans. The first SNS implant 
in a urological patient was performed by Tanagho and Schmidt at the university of California 
in San Francisco in 1982. After that, in 1994 InterStim received the CE mark for treatment of 
chronic functional disorders of the pelvis, lower urinary and intestinal tract in Europe. In 1997 
Interstim received a FDA approval for treatment of urgency urinary incontinence in the USA 
which was expanded in 1999 for treatment of symptoms of urgency-frequency and urinary 
retention. In 2002 the tined lead was introduced in SNS therapy to diminish the migration 
change of the lead.  
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Mode of action
The precise mode of action of SNS is unknown. There are at least two presumed mechanism 
of action: The first one claims that activation of efferent nerve fibers to the striated urethral 
sphincter reflexively causes detrusor relaxation. [12] The second presumed mechanism states 
that activation of afferent nerve fibers causes inhibition of the voiding reflex at a spinal and/or 
supraspinal level; pudendal nerve afferents seem to be particularly important for the inhibitory 
effect on the voiding reflex. [13] In OAB the inhibition by SNS may, in part, modulate the sensory 
outflow from the bladder through the ascending pathways to the pontine micturition center, 
thereby preventing involuntary contractions by modulating the micturition reflex circuit but 
allowing voluntary voiding to occur. [14]
The assumption that there is not only an effect at the spinal level but that there is also a 
central effect is strengthened by studies that are performed in complete spinal cord patients 
versus incomplete spinal cord patients. Schurch, [15] performed a PNE test in 3 complete SCI 
patients, after stimulation with a lead in the S3 foramen a good anal reflex was seen but after 5 
days of stimulating no improvement was observed in detrusor hyperreflexia. Hohenfellner, [16]
concluded in his study to chronic sacral neuromodulation that only the patients with nearly 
complete or complete spinal lesions seem unlikely to benefit from this treatment. 
Procedure 
The procedure can be preceded by a preliminary test phase referred to as a percutaneous 
nerve evaluation (PNE). This test uses a non-anchored test-lead placed in the S3 foramen and 
connected to an external stimulator. The test extends between 4 and 14 days, after which the 
lead is removed. Success of this test phase is generally defined as improvement of at least one 
major voiding symptom by more than 50%. The overall response rate for PNE is around 55%. 
Lead migration is considered the main factor of false negative results. [17] A true negative 
response to PNE of about 20% can be explained because the pudendal nerve afferents seem 
to be particularly important for the inhibitory effect on the voiding reflex and those afferents 
are confined to the S2 level only in 18% of all subjects. [18, 19]
SNS is nowadays often preformed in a two stage-technique with a quadripolar lead with 
self-anchoring tines, first described by Spinelli et al in 2003. [20] This technique enables test-
stimulation to be performed using the permanent anchored lead that reduces the risk of 
migration. This lead is usually placed through the back skin in the S3 foramen at sacral level 
(figure 1) and tunnelled subcutaneously, where it is connected to a temporary extension lead 
that exits the body and is connected to an external test stimulator. (figure 2) This test period 
mostly extends to 1-2 weeks. If the voiding symptoms improve by more than 50%, the subject 
might undergo surgery to implant the internal pulse generator (IPG). (Figure 3)
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Figure 2.
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Figure 3.
Testfase: PNE versus 1st stage Tined lead
Leong et al, [21] compared the patients response rate to PNE versus 1st stage Tined lead 
procedure. Eighty-two patients, comprising 69 OAB patients, were screened with both PNE 
and with a 1st stage tined lead procedure. More than 50% improvement in at least two relevant 
urinary symptoms was considered a positive response. The positive response rate on PNE was 
47% while 1st stage tined lead showed a 69% positive response rate. All patients with a positive 
1st stage tined lead received SNS treatment. Failure rate after 2 years was 2.9%. This study may 
suggest that 1st stage tined lead is a more sensitive screening rate method for SNS therapy. 
Long term effect
Long term data about the success rates of SNS are scarce. Van Kerrebroeck et al, [22] published 
a prospective multicentre trial evaluating the long-term safety and efficacy of SNS in patients 
with refractory urgency incontinence, urgency-frequency and retention. A total of 17 centre’s 
worldwide enrolled 163 patients for test-stimulation, of whom 152 patients received the 
implantation using Interstim. Voiding diaries were collected annually and clinical success was 
defined as ≥ 50% improvement from baseline in primary voiding diary variables. After 5 years 
105 patients completed the follow up and of them 87 completed the voiding diary. 68% of 
patients with urgency incontinence, 56% with urgency-frequency and 71% with retention had 
successful outcomes.
Groen et al, [23] published the 5 year results of SNS in 60 women with refractory idiopathic 
urgency urinary incontinence. A non-tined lead procedure was used and success was defined 
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as at least a 50% decrease in the number of incontinence episodes or pads used daily. At 5 
year SNS was still used in 48 (80%) patients of which 31 completed the voiding diaries. The 
success rate, patients with at least a 50% decrease in the number of incontinence episodes or 
pads used daily, gradually decreased from 52 patients (87%) at 1 month to 37 (62%) at 5 years. 
Complete continence persisted in 15% of patients. 
As with all treatments adverse events in SNS therapy are described, [24, 25] this mainly 
encompassed pain, infection, bowel dysfunction and change in clinical effect often due to 
lead migration. Based on the summarized adverse event data, many wound complications 
and some changes in efficiency can be managed conservatively without repeated surgery. 
Published rates of infection range from 0% to 11% in various studies. [26] Rates of surgical 
revision and explanations vary in literature. 
There is a decline in therapy effect of SNS over the years. If patients are successfully treated with 
SNS the battery will eventually empty and a surgical intervention to change the battery will 
be necessary. The typical battery life of Interstim I is 8–10 years; depending on the parameters 
used for stimulation. The expected lifespan of Interstim II lies around 3–5 years when used 24 
hr/day. There is also a percentage of patients treated with SNS who, after a few years, don’t 
benefit from their therapy despite of adequate nerve stimulation. A suggested hypothesis for 
this phenomenon is habituation of the nerve system to prolonged stimulation of the sacral 
nerve.  
If on demand stimulation would be possible it will lead to a longer battery life and it may 
decrease the risk of habituation of the nervous system. To answer this question, Oerlemans 
et al [27] completed a pilot intervention study for on-demand SNS in patients with urgency 
incontinence and urgency-frequency syndrome. Twenty-one patients participated of which 
5 were randomized into a control group (continuous stimulation) and 16 into the on-demand 
group. The on-demand group was asked to switch the device off, and on again, when they felt 
recurrent symptoms. Of the study group, 10 patients reported no worsening of the symptoms 
by on-demand sacral nerve stimulation. The mean off-time was 12.4 hours. The other six had 
worsening of their symptoms. Larger randomized studies with longer follow- up are needed, 
but this pilot study suggests that in the majority of patients on-demand SNS treatment could 
be possible, implying less battery changes and therefore lower therapy costs. If on-demand 
stimulation reduces the decline in therapy effect over the years due to habituation of the 
nervous system it could give better long term results. 
Costs
There are several publications about the cost effectiveness of the treatment for OAB, in particular 
for PTNS and SNS. Various articles show different costs, since the medical care systems differ 
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between countries. Leong et al, [28] published that the cost of SNS as a treatment for OAB 
syndrome in the Netherlands is $15.743 over a 2 year time period. D’Ausilio et al, [29]calculated 
the 10 years cost for SNS in Italy at €33.897. Staskin et al, [30] compared the costs of PTNS to SNS 
for OAB syndrome in the USA. PTNS was the least costly with $7.565 for a three year treatment, 
compared to SNS which costs $24.681 for the same treatment period. Martinson et al, also 
concludes that PTNS had substantially lower costs compared to SNS in the USA. Although it’s 
difficult to compare between countries the treatment costs for SNS seems to be are higher 
compared to PTNS treatment.
practical advice:
•	 If you want to apply SNS therapy, you need a passionate and motivated team. Especially 
the first year you and your team will see the patients frequently for the implantation and to 
apply the best program for their therapy. It can be time-consuming, but good and precise 
settings can lead to a very satisfying therapy. 
•	 Before the implantation inform your patient about the expectations, the procedure, the 
long-term results and the possible complications. 
•	 With strict selection criteria you will have a high success rate. But in less clear cases, who 
have tried other therapies, you can give them the benefit of the doubt by performing a 
test-phase with a PNE or a tined lead, and still keep strict implantation criteria. Offering 
the patients a test-phase will help to treat them, or when it does not work, to accept their 
problem. 
•	 Take your time with implanting the lead to confirm the right position. If you perform it under 
local anesthesia ask for the sensory response. If you implant under general anesthesia, 
make sure no muscle relaxant is used, because the motor response is the only response 
you can rely on. 
•	 Yes it’s expensive, but for patients the result can be priceless.
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Abstract
Objectives
To evaluate the effect of subject-controlled, on-demand, dorsal genital nerve stimulation on 
non-neurogenic urgency urinary incontinence in a domestic setting.
Methods
Non-neurogenic patients >18 years with overactive bladder symptoms and urgency urinary 
incontinence were included. Exclusion criteria were mainly stress urinary incontinence. Patients 
underwent one week of subject-controlled, on-demand, dorsal genital nerve stimulation, 
delivered by a percutaneously placed electrode near the dorsal genital nerve connected to 
an external stimulator (pulse-rate 20 Hz, pulse-width 300 μs). Patients activated the stimulator 
when feeling the urge to void and stimulated for 30 s. The amplitude was set at the highest 
tolerable level. A bladder diary including a severity score of the urgency urinary incontinence 
episodes/void (scores: 0=none, 1=drops, 2=dashes, 3=soaks) and a padtest was kept 3 days 
prior to, during, and 3 days after the test period. The subjective improvement was also scored.
Results
Seven patients (4 males / 3 females) were enrolled, the mean age was 55 years (range 23-73). 
Six completed the test week. In the remaining patient the electrode migrated and was 
removed. 5/6 finalized the complete bladder diary, 1/6 recorded only the heavy incontinence 
episodes (score=3). 4/6 completed the padtest. In all patients who finalized the bladder diary 
the number of urgency urinary incontinence episodes decreased, in 3/5 with ≥60%. The heavy 
incontinence episodes (score=3) were resolved in 2/6 patients, and improved ≥ 80% in the 
other 4. The severity score of the urgency urinary incontinence episodes/void was improved 
with ≥60% in 3/5 patients. The mean subjective improvement was 73%. 
Conclusion
This feasibility study indicates that subject-controlled, on-demand dorsal genital nerve 
stimulation using a percutaneously placed electrode is possible over a longer time period, 
in a home setting, with a positive effect on non-neurogenic overactive bladder symptoms 
with urgency urinary incontinence. Although the placement is an easy procedure, it is difficult 
to fixate the electrode to keep it in the correct position. Improvements in hardware, like a 
better fixated electrode and an easy to control stimulator, are necessary to make SODGNS a 
treatment possibility in the future.
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Introduction
In patients with urgency urinary incontinence (UUI) the time between the sensation to void 
and reaching the toilet is mostly too short to prevent incontinence. UUI is often challenging to 
treat and affects the quality of life of many people negatively.
Conservative treatment comprises bladder and behavioral training with or without 
anticholinergics or mirabegron. Side effects, like dry mouth and constipation, strongly decrease 
compliance of patients to treatment, are an important reason to discontinue treatment.[1] More 
invasive treatments can be considered in patients who do not tolerate side effects or who 
do not respond satisfactorily. Intravesical injections of Botulinum toxin and neuromodulation 
are examples of more invasive or surgical treatment. Drawbacks of intravesical injections of 
Botulinum toxin are the temporary effect which demands repeated injections and the risk 
for residual urine or urinary retention with the need for self-catheterisation. With regard 
to neuromodulation are Percutaneous Tibial Nerve Stimulation (PTNS) and Sacral Nerve 
Stimulation (SNS) nowadays widely adopted as a treatment which diminishes UUI [2-5]. With 
PTNS a moderate or markedly result is seen in 55% of the patients [3], however PTNS is a rather 
time consuming therapy. Patients need to visit the office once a week for 12 weeks. A electrode 
needle has to be inserted correctly for each stimulation session. To maintain the treatment 
effect patients need to continue their visits more than once a month. [4] With SNS therapy the 
success rate, ≥ 50% improvement, is around 62% - 68%. [2, 5] Complete continence is reached 
in only 15% of the patients. [2]
Dorsal genital nerve (DGN) stimulation has been used in research settings and seems to be 
promising for future use in clinical care.[6-8] The DGN, being the dorsal penile nerve (DPN) or 
clitoral nerve (DCN), is a terminal branch of the pudendal nerve . Previous studies have shown 
that DGN stimulation can inhibit involuntary bladder contraction in an acute investigational 
setting. [9, 10] When inhibition of the detrusor contraction can be effectuated with on 
demand DGN stimulation in a domestic setting, complete continence could theoretically 
be achieved. Using on demand stimulation to inhibit an involuntary detrusor contraction 
the patient gains time to reach the toilet. A study on subject-controlled, on-demand, dorsal 
genital nerve stimulation (SODGNS) through self-adhesive surface electrodes in neurogenic 
patients with detrusor overactivity who had intact bladder sensations showed a reduction 
in their UUI episodes during five days of stimulation at home. [11] Another study used a 
percutaneous electrode for continuous stimulation at home in non-neurogenic women 
with UUI, who also reported a reduction in UUI episodes[7]. The results of subject-controlled 
on-demand stimulation with an implanted electrode in non-neurogenic patients with UUI 
in daily life are not known yet. Previous studies used continuous stimulation instead of 
on-demand stimulation, included patients with neurogenic detrusor overactivity instead of 
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non-neurogenic UUI, or only acute effects of on-demand stimulation in a laboratory setting 
were used instead of application in a out of hospital setting with daily activities.[9, 11]
The purpose of the current study was to investigate the effect of SODGNS on overactive 
bladder (OAB) with UUI in a home testing period using an implanted electrode in non-
neurogenic patients with refractory OAB and UUI.  
Methods
The study was approved by the accredited medical research ethics committee, Committee 
on Research Involving Human Subjects region Arnhem-Nijmegen (The Netherlands) and 
written informed consent was obtained. The inclusion criteria were: age >18 years old, OAB 
with UUI, and more than 4 UUI episodes a day, patients who are willing and aiming to follow 
all requirements of the protocol. The exclusion criteria: Neurogenic OAB, pure stress urinary 
incontinence, neurological disease, skin lesions at the implantation site, an increased risk of 
infections, poor wound healing, bleeding tendency, DGN or pudendal nerve or sacral root 
lesions, a cardiac pacemaker, peripheral neuropathy, and pregnancy.
Patients on anticholinergics had a wash-out period of 2 weeks. All patients kept a bladder diary, 
a pad test and scored once daily the Patient Perception of Intensity of Urgency Scale (PPIUS), 
3 days prior to and during the 7 days home stimulation days. The bladder diary contained 
frequency, micturition volume, intake and the severity of urgency urinary incontinence 
estimated by the Severity Score of Incontinence Episodes (SSIE) (0= none, 1= drops, 2= dashes, 
3= soaks). At the end of the SODGNS week, the subjective improvement was scored. All subjects 
underwent a test period of SODGNS for four hours using self-adhesive skin electrodes. In males 
we used 25 mm-diameter round PALS electrodes, (Axelgaard manufacturing Co., Fallbrook, 
CA,). The cathode and anode were placed, proximally and distally, respectively, on the dorsum 
of the penile shaft. In females a PALS electrode was positioned next to the clitoris as anode 
and a Neuroline700 (Ambu, A/S, Ballerup, Denmark) as cathode on the clitoris (figure 1).
The electrodes were connected to a handheld battery powered current controlled stimulator 
(Odstock O2CHS, Salisbury, Wiltshire, UK). Stimulation was initiated by pushing a button and 
lasted for 30 s. They started stimulation every time as soon as they felt the need to go to the 
toilet to pass urine. However, when they were at the toilet and wanted to void, they did not 
activate the stimulator and voiding could proceed as normal. The stimulator was set to square 
pulses at a pulse-rate of 20 Hz and a pulse-width of 300 μs. The stimulation amplitude was 
set at the highest tolerable level. If during the test period with surface electrode stimulation 
the UUI decreased subjectively they underwent percutaneous placement of an electrode 
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(Medtronic InterStim Model 3057 Test Stimulation Lead, Minneapolis, USA ) under local 
anesthesia (lidocaine 1%). The electrode placement was performed in the outpatient clinic. 
Firstly, a needle electrode was inserted in the pubic area in the direction of the clitoris or the 
penile base. Test stimulation was applied and patients were asked where the stimulation was 
felt. If the patient reported a sensation localized at the clitoris or at the glans penis, it was 
concluded that proper placement was obtained (figure 2). After proper needle positioning 
the lead was introduced, fixated to the skin and connected to an external voltage controlled 
stimulator (Medtronic inc, Model 3625, Minneapolis, USA). The stimulator was set to square 
pulses at a pulse-rate of 20 Hz and a pulse-width of 300 μs. This stimulator was activated 
by turning the amplitude control button to its maximum and was turned off by turning the 
control button back to 0. The maximum was limited to the patient’s highest tolerable level. 
The patients were sent home for one week. Conform the instructions for the test period 
patients were asked to stimulate every time as soon as they felt the need to go to the toilet to 
pass urine for 30 s. Improvement was defined as ≥ 60% reduction in UUI episodes. 
Results
Seven patients , 4 males and 3 females were enrolled. The mean age was 55 years old (range 
24-73). All patients had a positive result on their UUI during the test-stimulation with skin 
electrodes and subsequently an electrode was implanted. The implantation took 10-40 
minutes. In 4 patients the electrode dislocated after stepping off the treatment bench where 
after upon stimulation the sensation in the desired location was gone. In those patients a new 
electrode was placed.
At the time of lead placement, the stimulus amplitude at which the subject first felt the stimulus 
(sensation threshold) was 1.6 ± 0.8 V (range 1-3 V), and the maximum tolerable amplitude was 
7.6 ± 2.2 V (range 6-10 V). Six out of 7 patients completed the protocol. One patient did not feel 
the sensation in the proper position after 2 days of home stimulation, likely due to migration 
of the electrode, and the electrode was removed. At the end of the week of stimulation the 
sensation threshold amplitude was higher but not clinical significantly (1.8 ± 0.4 V, range 1-2 V).
Three out of 6 patients reported that the location of sensation had slightly changed during 
the week of home stimulation, where after the subjective effect of stimulation on their UUI 
was slightly less.
Of the 6 patients who completed the week of home stimulation, 4/6 completed the padtest, 
all completed the PPIUS, 5/6 finalized the complete bladder diary and the remaining one 
recorded only the heavy IE (3=soaks) and the nighttime frequency in her bladder dairy.
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Results are shown in table 1, and the results per patient per day are shown in table 2. 
The heavy IE (3=soaks) resolved completely in 2/6 patients, and 4/6 patients had a ≥80% 
improvement of the heavy leaks (91%, 81%, 80%, and 80%).
In all of the 5 patients who finalized the complete bladder diary the number of UUI episodes 
decreased. In 3/5 it improved with ≥ 60% (94%, 88%, 60%) the other 2 improved with 16% and 
4%. The SSIE/void was improved with at least 60% in 3/5 patients (95%, 83%, 74%) the other 2/5 
patients had an improvement of 41% and 20%.
In 4/5 patients the daytime frequency decreased. The mean number of voids per day with 
and without SODGNS were 10 (range 5–14) and 11 (range 7–16), respectively. The nighttime 
frequency decreased in 5/6 patients, and was unchanged in the remaining one. 
The voided volume per day during the test week was comparable to the days before the test 
week, 1809 (±346) ml/day respectively 1821 (±553) ml/day. The mean voided volume (MVV) 
increased in 4/5 patients. The MVV with SODGNS was 223 (±148) ml and without SODGNS 184 
(±93) ml.
The PPIUS improved in 5/6 patients. All patients used pads for their incontinence, 4 completed 
the padtest. Of the 4 subjects who completed the padtest, 2 had at least 60% improvement 
(99% and 73%) the other two had both 27% improvement. The subjective improvement 
reported by the patients were: 100%, 90%, 80%, 70%, 70%, and 30%.  
Patients mentioned that the SODGNS had a better effect, when the stimulator was activated 
without delay in response to the urge to void. They also mentioned that with the button 
they had to turn activating the stimulator which was used during the test week, was more 
inconvenient compared to the pushbutton, which was used during the 4 hour test period 
with the skin electrodes.
After the stimulation week, one patient reported that the effect on the UUI was immediately 
gone and 5/6 patients reported that the effect waned over time. They reported to have a 
decreasing effect over a time period from 1-7 days.
During the week of home stimulation 1 patient experienced a mild muscle pain in her pelvic 
floor. One patient experienced a headache at the first day and one patient had one day of 
chest pain, cardiac evaluation showed no abnormalities. At explantation of the electrode 4/6 
patients had a temporary small hematoma and in 1 patient some redness at the implantation 
site was observed. All resolved spontaneously.
103 
Subject-controlled, on-demand, dorsal genital nerve stimulation to treat urgency urinary incontinence; a pilot study
C
h
ap
te
r 
5.
1
Table 1: Mean of variables of the days prior to stimulation and the days during of SODGNS.
Patient 1 2 3 4 5 6
Gender M M F F M F
Mean number of IE/day Before SODGNS 14.0 6.0 - 8.3 17.7 8.0
SODGNS 13.5 0.7 - 3.3 14.8 0.5
Improvement (%) 4 88 - 60 16 94
Mean heavy leaks/day Before SODGNS 1.0 1.0 3.3 2.7 5.0 2.3
SODGNS 0.2 0.0 0.3 0.5 1.0 0.0
Improvement (%) 80 100 91 81 80 100
Mean SSIE/void Before SODGNS 2.0 0.6 - 1.9 2.2 2.2
SODGNS 1.6 0.1 - 0.5 1.3 0.1
Improvement (%) 20 83 - 74 41 95
Mean padtest (g/day) Before SODGNS 63.0 - 402.7 76.0 - 313
SODGNS 16.7 - 295.2 55.8 - 3.3
Improvement (%) 73 - 27 27 - 99
Mean daytime frequency Before SODGNS 14.0 10.7 - 8.3 15.7 7.0
SODGNS 14.0 8.0 - 8.0 13.8 5.0
Improvement (%) 0 25 - 4 12 29
Mean nighttime frequency Before SODGNS 0.3 3.3 2.7 1.0 2.0 1.0
SODGNS 0.0 2.2 1.5 1.0 1.3 0.2
Improvement (%) 100 33 44 0 35 80
Mean PPIUS Before SODGNS 3.0 3.5 4.0 3.8 3.2 4.0
SODGNS 2.0 1.3 2.5 2.1 3.3 2.5
Improvement (%) 33 67 38 45 -3 38
Subjective improvement (%) 90 70 70 80 30 100
SODGNS: subject-controlled, on demand dorsal genital nerve stimulation
SSIE: Severity Score of Incontinence Episodes
PPIUS: Patient Perception of Intensity of Urgency Scale
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Table 2: Mean SSIE / void per day and mean Pad test per day
Patient 1 2 3 4 5 6
Gender M M F F M F
SSIE/void Before SODGNS 1 2.1 0.9 - 1.4 2.2 2.3
2 1.9 0.5 - 2.1 2.1 2.4
3 2.1 0.4 - 2.1 2.3 2.0
SODGNS day 1 1.3 0.0 - 1.0 1.3 0.0
2 1.7 0.0 - 0.3 1.2 0.0
3 1.6 0.1 - 0.6 1.5 0.0
4 1.7 0.2 - 0.4 1.3 0.2
5 1.6 0.1 - 0.3 1.2 0.3
6 1.7 0.1 - 0.6 1.2 0.2
Padtest (g/day) Before SODGNS 1 59 - 450 114 - 315
2 59 - 450 38 - 315
3 57 - 338 - - 324
SODGNS day 1 13 - - 160 - 0
2 32 - 336 6 - 0
3 15 - 364 64 - 0
4 15 - 200 70 - 8
5 11 - 334 12 - 5
6 14 - 242 23 - 7
SODGNS: subject-controlled, on demand dorsal genital nerve stimulation
SSIE: Severity Score of Incontinence Episodes
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Discussion
This pilot study demonstrates a decrease in UUI with subject controlled, on demand DGN 
stimulation using a percutaneously placed electrode in patients with idiopathic refractory UUI 
in a home setting. One patient was almost 100% dry, she described that she was completely 
dry except for the moments when she wasn’t able to activate the stimulator immediately 
when she felt the urge to void, e.g. because she was driving her car or first had to undo her 
coat to reach the stimulator. The other patients also mentioned that the SODGNS had a better 
effect, when the stimulator was activated without delay in response to the urge to void. This 
was difficult to achieve in every episode since the stimulator was in most of the time in their 
pocket, which always gave a little delay. Patients also mentioned that the button they had to 
turn on for activation of the stimulator was more inconvenient compared to the pushbutton, 
and therefore more time consuming and causing delay. Probably, better results would 
have been achieved with a quicker and easier activation of the stimulator. This implies that 
immediate stimulation when feeling urge is important. This is in line with Opisso’s report in 
2008.[12] He described that in patients with neurogenic detrusor overactivity, the sooner the 
onset of DGN stimulation during a detrusor contraction, the greater the likelihood of stopping 
the contraction and therefore preventing incontinence. Ideally, instead of manually turning 
or pushing a button while feeling urge, a sensor that continuously monitors bladder activity 
should be used to set off the conditional stimulation. In this way a closed loop system could 
be formed. There is ongoing research into bladder sensors, but until now no suitable device is 
available for clinical application. [13]
Besides the decrease in UUI, the daytime and nighttime frequency also decreased with 
SODGNS. The mean volume/void increased. This supports the assumption that patients can 
suppress the urge to void with SODGNS, and gain time before they have to go to the toilet, 
and gain time to reach the toilet without UUI.
Another advantage of conditional compared to continuous stimulation is that the stimulation 
is only felt when activating the stimulator during the sensation of urge instead of feeling the 
stimulation continuously. The sensation of the stimulation was experienced as less annoying 
by the patients than the sensation of urgency. During an urgency episode the stimulation 
amplitude was experienced less intense, therefore the amplitude of SODGNS can be set to a 
higher amplitude compared to continues stimulation. With a higher stimulation amplitude a 
better effect on the bladder inhibition could be achieved and therefore a higher continence 
rate can be expected. Another further advantage is that SODGNS reduces power consumption 
compared to continuous stimulation due to reduction in stimulation time.
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This study is performed in non-neurogenic OAB patients. Previous DGN stimulation in a 
domestic setting has been described in neurogenic OAB patients with comparable results.
[11, 14, 15]. Opisso performed SODGNS, through self-adhesive skin electrodes, in patients with 
intact bladder sensation and described a decrease in their UUI [11]. Lee, et al [14] published 
a case report of SODGNS with skin electrodes in a 33 year old spinal cord injured (SCI) male. 
SODGNS diminished his UUI episodes. Continuous DGN stimulation is described by Wheeler 
et al, [15] in this study 2 males with SCI and UI due to detrusor overactivity fulfilled 2 weeks of 
continues DGN stimulation through surface electrodes and became continent.
Comparing this study with SODGNS to the publication of Goldman et al [7] who performed 
continuous DGN stimulation in non-neurogenic patients a stronger effect on UUI was found 
with SODGNS in our patients, although both studies contained only a small number of patients 
and results must be interpreted carefully. With continuous DGN stimulation 79% of the patients 
experienced a reduction in UUI episodes of whom 47% experienced a ≥ 50% reduction in UUI 
episodes. With SODGNS all patients experienced a reduction in incontinences episodes and 
a ≥ 50 % reduction was seen in 60% of the patients. The number of heavy leaks decreased 
with ≥ 50% in 85% of the patients with continuous DGN stimulation, with SODGNS this was 
seen in all patients. Eighty-eight % of the patients experienced a reduction in pad weight with 
continues DGN stimulation. Of them 76% experienced at least 50% reduction. With SODGNS 
all patients who completed the padtest had a reduced pad weight and half of them (2/4) with 
at least 50%. Although this is a pilot study with a small number of patients SODGNS might 
have better results as compared with continuous DGN stimulation.
In this study we used self-adhesive skin electrodes for the test period. All patients who were 
included for this study responded during this test period. Lee et al [10] showed that there is 
no difference between conditional DGN stimulating with surface electrodes comparing to 
percutaneous placed electrodes. So if SODGNS would be possible with an definitive implant, 
the screening period before implanting, the PNE or 1st stage tined lead for SNS, can be done 
with less invasive surface electrodes. 
All subjects tolerated the DGN stimulation well. Patient’s commends were about the usability 
of the technique, especially of the activation system as mentioned above. Theoretically, 
damage to the nerve or infection by the percutaneous electrode could occur. Only minor 
adverse events were noticed during short-term follow-up. Up to now no long-term results of 
electrodes near the DGN are available because of only acute settings or short-term follow-up 
in SODGNS studies, besides studies and experiences with PTNS and SNS. The setting of 
the current study would intervene with sexual intercourse and a complete implant with 
an electrode that doesn’t migrate would therefore be desirable. In previous studies DGN 
107 
Subject-controlled, on-demand, dorsal genital nerve stimulation to treat urgency urinary incontinence; a pilot study
C
h
ap
te
r 
5.
1
stimulation did not evoke sexual feelings or responses.[6, 7] As patients use the stimulation 
only on demand, the stimulation does not interfere with intercourse as long as the stimulation 
is not activated by the patient, which is less likely to be needed during sexual intercourse due 
to sexual stimulation of the DGN. The influence of long-term DGN stimulation on sexuality 
is not known. Continuous DGN stimulation might theoretically desensitize sexual responses. 
With SODGNS this risk of desensitizing might probably be lower, due to less and intermittent 
stimulation.
One patient could not complete the week of home stimulation due to dislocation of the lead. 
Of the six patients who completed the week of SODGNS, 3 reported that the sensation had 
slightly changed from position during the week of home stimulation where after the effect 
subjectively deteriorated slightly. This shows that this percutaneously placed lead is not very 
prone to stay in the initial location. For future treatment an electrode with a more stable 
position is necessary. An percutaneous lead connected to an external stimulator is not ideal 
nor patient friendly. Further development requires at least a fully implanted system consisting 
of an electrode and a pacemaker, which can be activated by a wireless activator that is easy 
to use.
Conclusion
This feasibility study indicates that it is possible to administer SODGNS using a percutaneously 
placed electrode, over a longer time period, in a home setting, with a positive effect on 
OAB with UUI. The electrode can be placed in an outpatient setting by a minimal invasive 
pre-pubic approach and is well tolerated by the patients. Although the placement is an easy 
procedure it is difficult to fixate the electrode to keep it in the correct position. Improvements 
in hardware, like a better fixated electrode and an easy to control stimulator, are necessary to 
make SODGNS a treatment possibility in the future. 
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Abstract
Introduction
This study is designed to investigate the safety and performance of a new implantable system 
for tibial nerve stimulation for overactive bladder symptoms.
Methods
A battery-free stimulation device for tibial nerve stimulation (BlueWind Medical Ltd.) was 
implanted in 15 patients. Safety and efficacy assessments were done at 3 months after 
activation with a 3-day bladder diary, a 24-hour padtest and 2 quality-of-life questionnaires.
Results
Two males and 13 females were enrolled. Mean age was 54 years (range 19-72). Five/15 patients 
were previously treated with percutaneous tibial nerve stimulation. Twelve/15 patients 
experienced urgency urinary incontinence. The median operation time was 34 minutes. After 
three months follow-up a significant change was seen in: 24-hour frequency (p=0·002) from 
11·8 times/day (±3·5) to 8·1 times/day (±2·0), the amount of severe urinary urgency episodes 
(p=0·002) from 6·5 times/day (±5·1) to 2·0 (±2·.1), severe incontinence episodes (p=0·017) from 
2·8 (±5·2) episodes/day to 0·3 (±0·4) episodes/day, urinary loss/day (p=0·038) from 243 grams 
(±388) to 39 grams (±55), and improvement in quality of life. After implantation, 3 patients had 
a prolonged antibiotic treatment and 3 patients used prolonged pain medication for 1 week. 
In one patient the device was explanted due to pain and swelling suspicious for infection, 
although tissue cultures did not reveal a bacterial infection.
Conclusions
This novel posterior tibial nerve stimulator is a safe and easy to implant stimulator with good 
clinical results. 
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Introduction
The International Continence Society has defined overactive bladder syndrome (OAB) as 
urinary urgency, usually accompanied by frequency and nocturia, with or without urgency 
urinary incontinence in the absence of urinary tract infection or other obvious pathologies.
[1] OAB has a negative impact on quality of life and successful treatment is difficult.[2] The 
use of neuromodulation as a treatment for OAB has developed over the years. The purpose 
of neuromodulation for the treatment of OAB is to target the innervation system that controls 
the pelvic floor organs and specifically the lower urinary tract. One of the neuromodulation 
treatments is percutaneous tibial nerve stimulation (PTNS).
PTNS is thought to deliver retrograde neuromodulation through the tibial nerve to the sacral 
nerve plexus via a percutaneous 34-gauge needle electrode. Treatment consists of 30 min 
of stimulation once a week for 12 weeks. In order to keep benefitting from the treatment 
responders have to continue their treatment. In the long term the optimal interval between 
stimulation sessions varies per person between 1-3 times a month, with an average of once a 
month. [3] Although PTNS is an effective treatment it, is an office application and therefore it 
is time-consuming for both the patient and the care-giver. 
A new PTNS implant has been developed recently by BlueWind Medical, Herzliya, Israel. 
The important advantage of performing PTNS by an implant is the possibility to apply PTNS 
treatment on demand at home, or any other preferred place, without the need to insert a 
needle. In this manuscript we describe the 3-month results of 15 patients treated with this new 
implant in our hospital.  
Materials and Methods
The study was approved by the local ethical committee and written informed consent was 
obtained. Patients between 18-80 years with symptoms of OAB with or without urinary urgency 
incontinence were recruited. Inclusion criteria were: medication refractory urinary frequency 
>8 times/24hours and/or urinary urgency incontinence episodes of at least 2 leaks on 3-day 
diary, and without clinical evidence of a neurological S2-S4 motor sensory deficit. Patients could 
have had successful PTNS in the past. Main exclusion criteria were: botulinum toxin injections 
in the past 6 months, nerve stimulation therapy for OAB treatment except for successful 
PTNS treatment, obvious clinically demonstrated genuine urinary stress incontinence, urinary 
incontinence surgery in the past 6 months, abdominoperineal resection of the rectum, pelvic 
pain disorder, neuropathy, current urinary tract infection and uncontrolled diabetes. 
The implant is wirelessly powered by an external control unit (ECU) that provides the 
therapeutic parameters. The ECU is only worn while delivering treatment. The implant is a 25 
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mm cylinder with a diameter of 3·4 mm and 4 small fixating wings. The cylinder consists of an 
electrical power receiver and two bipolar electrodes (figure 1). Stimulation can be performed 
with a pulse width between 50-800 µsec; a frequency of 5,10,20,40 Hz), and an amplitude in 
range 0-9 mA. Patients can adjust only the amplitude themselves between a patient-specific 
set minimum and maximum.
     
Figure 1a. The implant and its placement location 1b. The ECU position
With an open surgical procedure the implant was placed near the tibial nerve. Pre-operative 
prophylactic antibiotic was administered (Cefazoline 1000 mg). If percutaneous localization 
of the nerve with a needle electrode showed the proper motor response i.e. flexion of the 
hallux, fanning of the toes or extension of the whole foot, a skin incision of 5 cm was made 
approximately 3 cm superior and 2 cm posterior of the medial malleolus. The tibial bundle 
including the tibial nerve was identified and the electrode was placed near the nerve and 
attached with non-absorbable sutures to the fascia. A test stimulation with observing the 
motor response was performed, to check proper functioning and positioning of the electrode. 
A pressure bandage was applied for 24 hours and patients were instructed to slowly increase 
their walking activities after 24 hours. 
One month after the operation the system was activated using the standard starting 
parameters: a pulse width of 200 µsec and stimulation frequency of 20 Hz. The minimum 
amplitude was set to the amplitude with which patients had their first sensation of the 
stimulation, and the maximum amplitude was set at the highest tolerable level. Patients were 
asked to stimulate 6 times a week, for 30 minutes, at a comfortable amplitude. One month 
after activation the parameters were adjusted if necessary.
At baseline and during the follow up visits (1month, 3 months) patients kept a bladder diary 
for 3 days containing frequency, micturition volume, fluid intake and the severity of urgency 
episodes (1= no urgency , 5= highest urgency , >3 was defined as severe) and severity of 
urinary incontinence episodes (0= no leak, 1= drops, 2= small amount, 3= large amount). 
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Moreover the patients kept a 24 hour pad test for 3 days, scored the Patient Perception of the 
Bladder condition (PPBC) and filled out the ICIQ-FLUTS questionnaire and the UDI long form. 
The PPBC is a single-Item global measure for patients with OAB.[4] Patients are asked to rate 
their perceived bladder condition on a 6-point scale. The ICIQ-FLUTS consists of 12 questions 
concerning bladder filling, voiding and on incontinence.[5] The total sum score of the ICIQ-
FLUTS ranges from 0-48 (asymptomatic to very symptomatic). Each question is linked to a 
bother from 0-10 (no bother – maximum bother). The UDI long form consist of 19 questions 
concerning symptoms associated with lower urinary tract dysfunction, obstructive/ discomfort 
symptoms, irritative symptoms and stress-symptoms.[6] Responders are asked to indicate if 
they experience the symptom and if they do, the degree to which it bothers them. 
For statistical analysis the Wilcoxon signed rank test was used a p value of <0·05 was considered 
significant. 
Success was defined as more than 50% decrease in symptoms.
The study is registered in clinicaltrials.gov: NCT02299544.
Results
Two males and 13 females were enrolled. Mean age was 54 years (range 19-72). Five/15 
patients were previously treated with PTNS. Twelve/15 patients experienced urgency urinary 
incontinence (OAB-Wet). The median skin to skin operation time was 34 minutes (range 23-90). 
All patients were operated under general anesthesia. In one patient no proper response was 
found after stimulation of the tibial nerve during the implantation procedure at patient’s 
preferred side, therefore the device was implanted in the other leg. After implantation, 3 
patients had a prolonged antibiotic treatment for 1 week and 3 patients used prolonged pain 
medication for 1 week. In one patient (OAB-Wet) the implant was explanted uneventfully 
due to pain and swelling suspicious of infection, although cultures turned out negative after 
explantation. The results of the other 14 patients, of which 11 were OAB-Wet patients, were 
analyzed to determine success rates.
After activation the amplitudes of the minimal sensation and maximum tolerable levels were 
on average 2·4 mA (±1·1) and 7·0 mA (±2·5), respectively.
All patients stimulated ones a day, 6 times a week for 30 minutes. After one month follow up, 
in 9 patients the parameters were adjusted to improve efficacy.
At 3 months follow up 6 patients stimulated with 20 Hz and 200 µs. Four patients stimulated 
with 10 Hz and 200 µs, 2 patients with 5 Hz and 200 µs, 5 Hz and 800 µs and 1 patient with 40 
Hz and 200 µs. 
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The 3-months results are presented in Table 1. The 24 hour frequency decreased significantly 
(p=0·002) Eight/14 patients had a daytime frequency of ≤ 8/day at three months follow up. 
The mean micturition volume significantly increased The amount of severe urinary urgency 
episodes improved significantly (p=0·002All patients but one (13/14 patients) demonstrated 
>50% improvement in the number of severe urinary urgency episodes. 
Among the 11 OAB-wet patients 2 patient were completely dry at three months follow up. 
Four/11 had >50% improvement of the number of urinary incontinence episodes/day. Nine/11 
OAB-wet patients used pads at baseline. Mean urine loss in grams/24 hours decreased 
significant (p=0·038 Five/9 had >50% improvement of their urinary loss in grams/24 hours. 
Seven/11 suffered from severe incontinence episodes at baseline (score 3=large amount). This 
decreased significantly (p=0·017) Five/7 had >50% improvement of these severe incontinence 
episodes. 
The quality of life questionnaire measured with the ICIQ-FLUTS improved significantly (p=0·001). 
In 13/14 the ICIQ-FLUTS improved, in one patient it remained unchanged. The bother-score 
improved significantly (p=0·002). Eight/14 patients demonstrated >50% improvement in their 
bother-score. 
The quality of life questionnaire measured with the UDI improved significantly following 3 
months of treatment (p=0·004). In 12/14 the sum-score of the UDI-questionnaire improved, in 
2 patients it deteriorated. Five/14 demonstrated >50% improvement. 
The PPBC had also significantly improved at 3 months of treatment (p=0·002). In 12/14 patients 
PPBC improved while for the remaining 2 patients it remained unchanged. 
None of the patients reported difficulties in operating the system, in addition 
none of the patient reported pain at the implantation sites or walking disturbances at 3 
months follow up. 
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Table 1: Voiding and quality of life parameters before implantation and after 3 months and the 
proportion of patients who had >50% improvement.
mean (sd)
parameters per 24 hours   (p-score) baseline 3-months >50%
Number of voids (p=0·002) 11·8 (±3·5) 8·1 (±2·0) 57%***
Mean micturition volume (ml) (p=0·041) 158·5 (±58·7) 176·5 (±59·2)
Number of severe urinary urgency episodes (p=0·003) 6·5 (±5·1) 2·0 (±2·1) 93%
Number of urinary incontinence episodes* (p=0·091) 7·2 (± 5·0) 3·72 (± 3·7) 36%
Number of severe incontinence episodes* (p=0·017) 2·8 (±5·2) 0·3 (±0·4) 71%
Mean urine loss (gr)** (p=0·038)  243·1 (±388·2) 38·9 (±55·4) 56%
ICIQ-FLUTS (p=0·001) 18·9 (±6·9) 12·3 (±5·5) 29%
ICIQ-FLUTS bother (p=0·002) 58·1 (±24·1) 27·9 (±19·4) 57%
UDI (p=0·004) 112·5 (±43·6) 64·4 (±48·3) 36%
PPBC (p=0·002) 5·0 (±1·1) 3·7 (±1·3) 21%
*   = 11 OAB wet patients
**  =  9  OAB wet patients who used pads
*** = % of patients who returned to a normal daytime frequency of ≤8/day
Discussion
This new neuromodulation device for OAB has proven to be safe and effective. Our study 
shows that implant-driven tibial nerve stimulation is feasible with a significant improvement 
of most prominent subjective and objective OAB parameters. Moreover, implant driven tibial 
nerve stimulation has some beneficial properties that could be beneficial compared to those 
of the standard neuromodulation systems; PTNS and sacral nerve stimulation (SNS). One of the 
principal advantages of implant driven PTNS is that patients can treat themselves outside the 
hospital, at a convenient time, as often as necessary for the best therapeutic benefit, without 
the need for needle insertion. In addition, this novel PTNS implantable device is battery-less, 
thereby eliminating the need for surgical intervention to replace batteries.  
Large scale clinical studies, significant research and considerable number of publications 
were performed on the working mechanism and clinical efficacy of SNS. Therefore, this 
technique can be regarded as the comparator for neuromodulation for OAB. Substantial 
clinical improvement was reported by Kerrebroeck et al. one year following SNS treatment 
for urinary voiding dysfunction [7]. Following SNS a significant decrease was observed in 
the number of voids/day (from 19·3 (±7·0) at baseline to 13·0 (±7·9) at 1-year follow-up, in the 
number of incontinence episodes/day from 9·6 (±6·0) to 4·7 (±4·9), and in the number of 
severe incontinence episodes/day from 2·6 (±3·3) at baseline to 1·2 (±2·7). We hereby report 
comparable results with the BlueWind implant with the number of voids/day significantly 
decreasing from 11·8 (±3·5) to 8·1 (±2·0), the number of incontinence episodes/day significantly 
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decreasing from 7·2 (± 5·0) to 3·7 (± 3·7), and the number of severe incontinence episodes/ day 
significantly decreasing from 2·8 (±5·2) to 0·3 (±0·4). When comparing SNS results to the results 
in our study, several differences should be noted that are essential for interpretation of the 
clinical data. For example, the above mentioned SNS study was carried out on highly selected 
patients, who exhibited successful PNE before the SNS stimulator was implanted, indicating 
that only patients who responded favorably to this form of neuromodulation treatment were 
recruited. In our study only 36% was preselected, (5/14) of the patients had a successful PTNS 
treatment in their past, and 64% never received PTNS treatment before. In this small study no 
difference in outcome was seen between those two groups of patients, if this is also seen in a 
lager randomized controlled trial, maybe effort and money that is put into the pre-testing of 
patients may be unnecessary. 
An additional advantage the tibial nerve implant holds in comparison to SNS devices is 
the simple and short duration of the implantation procedure. The tibial nerve at the ankle 
level is easy to access, and the small and compact design of the implant minimizes pain at 
implantation site. Moreover the tibial nerve implant is leadless so lead breakage cannot occur 
in contrast to other implants. [8] 
Different studies report variable success rates following PTNS treatment, ranging between 
37-93%.[9-11]. The results in this study are comparable with the results of the SUmiT trial 
published by Peters et al in 2010 [12]. They described a significant change from baseline in 
voids/day of -2·4(± 2·5) as compared to the significant change reported herewith of -3·7 (±3·6), 
and a significant change of-1·3 was reported for urinary urgency incontinence episodes a 
whereas we report a significant change of -3·6 (±5·3). 
In 2006 van der Pal et al published preliminary results on experimental PTNS implant, the 
Urgent SQ [13]. The results of this study were very promising, but the used technique was old 
and because of good manufacturing practice requirements it was not possible to develop 
this further. In comparison to the Urgent SQ the modern tibial nerve implant is smaller, easier 
to implant, and has more options for stimulation parameters. This allows the system to be 
individually tailored for those patients who are difficult to treat and need specific stimulation 
parameters to achieve clinical success. 
Recently, Janssen et al examined the patients with the Urgent SQ still in place. [14] Nine years 
after implantation no pressure sores or pain complaints were observed. This is very promising 
for long-term expectations of the new tibial nerve implant especially considering the smaller 
size of the implant. 
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Apart from the objective improvements, patients were also very satisfied with the results of 
the system and their quality of life improved substantially. An improvement in bother-scores 
measured by the ICIQ-FLUTS and the UDI was shown in 13/14 patients and 12/14, respectively. 
A study which validated the UDI-6 for Dutch men and women showed that a decrease of 16.7 
points in the UDI score is considered ‘‘clinically relevant’’ in patients undergoing any treatment 
for urinary incontinence.[15] In this study the UDI decreased with a mean 48 points (±48) 
which is very substantial. 
This study, reporting initial results in the first group of patients who received the BlueWind 
implant, obviously has some short comings. The study was small, not randomized and had 
short-term follow-up. Nevertheless, it has demonstrated the safety of the treatment, and its 
results are satisfying in the group of patients with debilitating refractory OAB complaints. 
The new implant technique is potentially well suited to be implemented in nowadays practice. 
The short term results of this study have the potential for a larger, long- term controlled trial 
to conform these initial results in a lager study group. In this study the implantation was done 
under general anesthesia, but it is potentially possible to perform the implantation under local 
anesthesia which will make it an outpatient procedure. In this study patients stimulated once 
a day, 6 days a week. Future research is necessary to show how often stimulation is necessary 
to reach and maintain an optimal therapeutic effect.
Conclusions
This is the first study of a novel implantable tibial nerve stimulator. This new tibial nerve 
stimulation system is a safe and easy to implant stimulator. The clinical short term results show 
significant subjective and objective improvements in patient suffering from OAB.
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This thesis comprises aspects of overactive bladder (OAB) syndrome in clinical practice. 
The first part of the thesis focuses on OAB symptoms, it’s bother and prevalence. OAB is a 
complex of symptoms, it is defined as urinary urgency, usually accompanied by frequency 
and nocturia, with or without urgency urinary incontinence in the absence of urinary tract 
infection or other obvious pathology. The symptoms that form OAB syndrome are part of 
the more comprehensive lower urinary tract symptoms (LUTS) syndrome. The prevalence 
of OAB or LUTS varies with age and sex. Not only the prevalence but also the experienced 
bother varies per symptom. For example It is reported that urinary incontinence (UI) and 
storage symptoms, the OAB symptoms, score higher for bother than voiding symptoms. [1] 
When treating patients, or conducting therapeutic studies knowledge on prevalence of 
symptoms and the experienced bother is important to establish what can be considered 
as “normal” or physiologic to estimate what the therapeutic effect is.
In the first part a study to the prevalence of LUTS in young otherwise healthy nulligravid 
females and the accompanying burden is described. A prevalence of LUTS was found in 94.3% 
of individuals and only 5.7% of these women had no symptoms at all. The participants scored 
higher on the symptom scores than on the bother scores; this might imply that their perceived 
symptoms were not always annoying but may have been interpreted as physiological. For 
all symptoms a positive correlation was found between the frequency of experiencing that 
symptoms and it’s bother. The highest botherscores were given for urgency and incontinence. 
In other studies it is shown that women with urinary incontinence and overactive bladder 
symptoms score lower on physical and mental health scores and seek more medical 
attention for these symptoms, than women without these symptoms.[2-6] If the physical 
and mental scores are lower and patients seek more medical attention, it is reasonable to 
assume a parallel to more bother. This impaired quality of life, the accompanying burden, 
and associated treatment costs makes OAB an important research field to continue improving 
existing treatments and to develop new treatments. Several studies have been done on OAB 
symptoms and it’s burden. Unfortunately they are difficult to compare, since different studies 
use different cut off points for experienced symptoms and its bother and different tools to 
examine the prevalence. For the future it would be very interesting to find a way that every 
research has the same definition of bother and uses comparable ways to inquire this bother.
The second part of this thesis contains existing treatment modalities. Both neuromodulation 
treatment and botulinum toxin A (BTA) therapy show good treatment results. BTA targets the 
neurogenic factors that contribute to the pathophysiology of OAB by blocking the release of 
neurotransmitters from bladder afferent and efferent nerves. BTA treatment is an easy to learn 
and a frequently used treatment in urology departments. But even for a treatment that is 
considered to be simple we found that 93% of the urologists performing this treatment would 
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like to receive training in the theoretical and/or practical aspects of BTA treatment. There is still 
no consensus on the ideal template for injecting BTA into the bladder. The registration trials for 
onabotulinum toxin A (BOTOX) used a standardized application technique. For idiopathic OAB 
20, 0.5ml intradetrusor injections, and for neurogenic patients 30, 1ml intradetrusor injections 
were used both trigone-sparing. This does not imply that everybody uses the same technique 
as in these trials. Karsenty [7] performed a review among 13 experts from 10 countries about 
current clinical practice. It showed differences in used formulation of BTA, units of BTA, injection 
mapping, injection volume, the needle and cystoscope that is used. Literature shows that BTA 
can be applied using a various number and amount of injections, trigone-sparing or not, and 
suburothelial or intradetrusor injections. A disadvantage of BTA treatment is the necessity of 
repeated injections since the effect fades away in time. Until today no technique has been 
discovered that prolongs the duration of the effect of BTA treatment. 
Future studies are needed to define the best bladder location to inject BTA. The actual 
pathophysiologic mechanisms of OAB are still to be identified, but arrhythmic electrical 
activity has been detected in the bladder wall of OAB patients. It is suggested that these 
electrical waves start from a point of innervations: “a pacemaker” [8, 9]. What is appealing, is 
to localize one or more innervations points of the electrical activity in the bladder and inject 
BTA at these locations. We conducted a study to try to create an electroanatomical map of the 
bladder using a 3-dimensional the (3D) mapping system that is normally used in cardiology to 
project the electrical activity of the heart on electroanatomical maps. This electroanatomical 
map in cardiology allows to locate the propagation paths of cardiac arrhythmias. [10, 11] Our 
research was an unsuccessful attempt to find the bladder innervations points. More research 
into electroanatomical mapping of the bladder is necessary. In the future this might reveal 
crucial information about bladder pathophysiology for new management strategies for OAB 
and BTA application.
A disadvantage of BTA injections into the detrusor is the risk of the necessity for CIC. Detrusor 
injections of BTA impairs mainly parasympathetic and sensory fibers coursing the bladder 
wall. The parasympathetic inhibition may inhibit voiding contractions but it can cause urinary 
retention. A future development could be to only influence the sensory fibers. Intrathecally 
BTA administration could be an administration route to achieve this. Coelho et al, performed a 
study to intrathecally administered BTA in spinal cord injured rats. [12] The formulation of BTA 
used was BOTOX. They concluded that intrathecally administered BOTOX had a predominantly 
effect on bladder sensory fibers, which resulted in significant improvement in spinal cord 
injury-induced neurogenic detrusor overactivity without causing urinary retention. They 
measured the by BOTOX induced SNAP-25 cleavage, since the detection of cleaved SNAP-25 
(cSNAP-25) can be used as a reliable marker for BOTOX activity both in peripheral and central 
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nervous systems. [13] They observed that cSNAP-25 was restricted to the superficial dorsal 
horn of lumbosacral segments, where most sensory fibers terminate. In contrast, cSNAP-25 was 
not detected in motor or preganglionic parasympathetic neurons. Another exciting finding in 
this study was that also impairment of basic neural metabolisms in the cell body of sensory 
neurons was found as a mechanism of action of BOTOX. According to these last findings, we 
can expect that a future recombinant botulinum toxin with a strong specificity for sensory 
fibers might be used to effectively treat NDO without the risk of impairing parasympathetic-
mediated bladder voiding contractions. 
To diminish the burden for patients, perhaps an injection-free approach of delivering BTA 
into the bladder can be performed in the future. BTA is a large molecule and this limits its 
diffusion across the urothelium to target areas in the suburothelium and detrusor. For this 
reason study groups try to find BTA mixed with different agents to make it more permeable 
for the urothelium, or to use different application techniques such as electromotive drug 
administration (EMDA). EMDA utilises an electrical current to impart an accelerated, directional 
(towards the tissue) movement of ionized drugs in an intravesical solution, which might results 
in greater quantities of drugs being delivered to greater tissue depths than is achievable by 
passive diffusion.
One of those additive agents is DMSO. In the urologic literature, DMSO is known as a nonspecific 
anti-inflammatory agent that can penetrate and/or permeate the glycosaminoglycan layer of 
the bladder with direct effect on the detrusor muscle. Petrou et al, completed a phase 1/2 trial 
to evaluate the safety and potential efficacy of direct intravesical instillation of a BOTOX mixed 
with dimethyl sulfoxide (DMSO) solution for treatment of idiopathic detrusor overactivity in 
women. [14] This study showed that direct instillation of a BOTOX/ DMSO solution is safe. Given 
the promising results of this study in treating women with idiopathic detrusor overactivity, 
further evaluation of this novel technique in a randomized, placebo-controlled phase 3 setting 
is certainly justified. 
After having demonstrated that bladder uptake of BOTOX improved when the toxin was 
formulated with liposomes in a hyperactive bladder model in rats. Chuang et al, studied the 
effect of bladder instillations of liposome encapsulated BOTOX for OAB syndrome in humans.
[15] Clearly this treatment appears attractive and promising but its results with regards to 
cardinal symptoms of OAB such as urgency and urgency incontinence are disappointing.
After a successful trial in rabbits, Kajbafzadeh assessed the use of EMDA to deliver BTA 
instillation to bladders of children with myelomeningocele. [16] The procedure involved the 
use of BTA at 10 U/kg abobotulinum toxin A instilled into the bladder filled with sterile water 
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at maximal capacity and the use of EMDA for 15 min using a maximum current of 10 mA. 
Urinary incontinence improved in 80%, urodynamic parameters improved, and interestingly 
vesico-ureteric reflux and bowel function also improved.
As well as BTA treatment, sacral nerve stimulation (SNS) is a treatment modality which gives 
substantial clinical improvement for the patient. The first SNS implant in a urological patient 
was performed by Tanagho and Schmidt at the University of California in San Francisco in 1982. 
After that, in 1994 Interstim received the CE mark for treatment of chronic functional disorders 
of the pelvis, lower urinary and intestinal tract in Europe. In 1997 Interstim received a Food and 
Drug Administration (FDA) approval for treatment of urgency urinary incontinence in the USA, 
which was expanded in 1999 for treatment of symptoms of urgency-frequency and urinary 
retention. The precise mode of action of SNS is unknown but several theories have been 
published. It seems incongruent that one therapy can be universally applied to effectively 
treat such diverse conditions as retention and urinary urgency incontinence. Regardless of 
whether the lower urinary tract dysfunction involves storage versus emptying abnormalities, 
the pudendal afferent signalling seems to serve as a common crossroad in the neurologic 
wiring of the system. [17, 18] Developments in SNS continued over the years, which resulted 
in the introduction of the tined lead in 2002 to decrease the migration chance of the lead. For 
SNS treatment results varying from 56% to 86% are described in literature [19, 20]. If patients 
are successfully treated with SNS depletion of the battery will occur and a surgical intervention 
to replace the stimulator is necessary. There is a percentage of patients treated with SNS who, 
after a few years, don’t benefit from their therapy despite of adequate nerve stimulation. A 
suggested hypothesis for this phenomenon is habituation of the nerve system to prolonged 
stimulation of the sacral nerves. [21]
For future developments a rechargeable battery would diminish the surgical re-intervention 
rate, since replacing the stimulator is than less frequently necessary. At this moment a 
study is conducted to a new rechargeable neuromodulation system, the RELAX-OAB study 
(ClinicalTrials.gov NCT02620410). On demand stimulation could possibly be a solution to 
prevent habituation. Oerlemans et al [21] completed a pilot intervention study for on-demand 
SNS in patients with urinary urgency incontinence and urgency-frequency syndrome. Twenty-
one patients participated, of which 5 were randomized into a control group (continuous 
stimulation) and 16 into the on-demand group. The on demand group was asked to switch 
the device off, and on again when they felt recurrent symptoms during a period of 2 weeks. Of 
the study group, 10 patients reported no deterioration of the symptoms by on demand nerve 
stimulation. The other 6 had worsening of their symptoms. The mean battery off-time was 
12.4 hours. This pilot study suggests that in the majority of patients on demand SNS treatment 
could be possible. Larger randomized studies with longer follow-up are needed to see if on 
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demand stimulation reduces the decline in therapy effect over the years and therefore give 
better long term results.
For patients and physicians, it can be difficult to choose between BTA treatment or SNS. Both 
have their advantages and their disadvantages. For example, BTA treatment is compared 
to SNS a shorter procedure, but needs to be repeated every 6-10 months to maintain the 
treatment effect. SNS has compared to BTA treatment implant related complication such as 
pain or infection which could lead to removal of the implant. After BTA treatment a small 
percentage of patients temporarily need to perform self-catheterization. Recently the results of 
a comparative randomized clinical trial for BOTOX versus SNS have been published.[22] This trial 
concluded that among women with refractory urgency urinary incontinence, treatment with 
BOTOX compared to SNS resulted in a small daily improvement in episodes of urgency urinary 
incontinence per day (−3.9 versus −3.3) that, although statistically significant, is of uncertain 
clinical importance. In addition, BOTOX resulted in a higher risk of urinary tract infections (35% 
versus 11%) and the risk for the need for transient self-catheterizations. Regarding quality of life, 
participants who received BOTOX had greater improvements in the questionnaire for symptom 
related bother, as well as for treatment satisfaction and endorsement. These published results 
are short term results (6 months). Since the effect of BOTOX injections declines over time and 
repeated injections are necessary on average every 6-10 months. In my opinion longer follow 
up is necessary to draw solid conclusions comparing BOTOX to SNS treatment. Overall, these 
findings do not clarify which treatment modality gives the best outcome. My personal opinion 
is that the choice between these two treatments is more dependent on the patient then on 
the treatment modality. For some patients BOTOX is a better solution since they prefer to have 
a repeated short simple procedure as for others SNS is the best choice of treatment because 
they don’t want repeated procedures and don’t want the risk for CIC. 
Another accepted neuromodulation treatment modality is percutaneous tibial nerve 
stimulation (PTNS). PTNS is easy to perform procedure that can be executed in an outpatient 
setting. PTNS executes its neuromodulative effect through the tibial nerve via a percutaneous 
34-gauge needle electrode. PTNS neuromodulative effects are mediated by suprasacral 
centers of stimulus elaboration involving finally cortical associative areas. [23] Several reviews 
have been published about PTNS treatment in the past years [24-26], describing success rates 
between 37%-93%. None of these reviews describe serious treatment related adverse events. 
With the exception of the 3 year follow up in the STEP study [27] little is written about the 
long term effect of PTNS treatment. Although PTNS seems to be an effective treatment for 
OAB, it is time-consuming for both the patient and the caregiver. The patient has to travel to 
the hospital and stay there for at least 30 minutes and the caregiver has to perform the needle 
placement. A possible future solution for this would be tibial nerve stimulation through an 
implant. This will be described in the final part of this chapter 
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The final and for me the most exciting part of this thesis comprises experimental 
neuromodulation treatments. The challenge for new developments in neuromodulation 
treatments for OAB is to design a therapy that is minimal invasive, with low complication rates, 
no need for re-surgical interventions, that gives minimal burden during stimulation (side-
effects), and with good and stable long-term results.
Subject-controlled, on-demand, dorsal genital nerve stimulation (DGNS) could be one of those 
new developments. With subject-controlled, on-demand, DGNS the dorsal genital nerve (DGN) 
is stimulated. The DGN, being the dorsal penile nerve (DPN) or dorsal clitoral nerve (DCN), is a 
terminal branch of the pudendal nerve. In contrast to sacral nerves, the DGN only consists of 
sensory afferent nerves, and lies superficial near the clitoris or penis which makes it an easy to 
access nerve. Since the presumed main working mechanism of all types of neuromodulation 
is in afferent direction, the recruitment of as many afferent fibers as possible therefore makes 
sense. Previous studies have shown that DGNS can inhibit involuntary bladder contraction.[28, 
29]. The feasibility study addressed in chapter 5.1 indicates that subject-controlled, on-demand, 
DGNS using a percutaneously placed electrode is possible over a longer period of time, in a 
home setting, with a positive effect on non-neurogenic overactive bladder symptoms. The 
urgency urinary incontinence episodes decreased, the heavy urinary incontinence episodes 
decreased, and the severity of the urgency urinary incontinence episodes/void improved. 
Patients were pleased with the results and did not experience the stimulation as annoying 
or painful. Although the placement is an easy procedure, it is difficult to fixate the electrode 
to keep it in the correct position near the DGN. Dislocation from the proper position showed 
a decrease in stimulation effect. Besides the chance of dislocation, another disadvantage 
is that in the studied setting DGNS intervenes with sexual intercourse. Since the electrode 
is prone to dislocate, subjects were asked to avoid unnecessary movements in that area or 
sportive/sexual activities. It is important to note that subject-controlled, on-demand, DGNS 
itself does not seem to intervene with sexual activities. This has two explanations: first the 
fact that patients use the stimulation only on demand, the stimulation itself does not interfere 
with intercourse as long as the stimulation is not activated by the patient. Stimulation is less 
likely to be necessary during intercourse due to sexual stimulation of the DGN, which already 
gives some inhibition of the bladder. Secondly, Previous studies showed that during DGN 
stimulation, with the stimulation parameters used in this study, no sexual feelings or responses 
are provoked.[29, 30]. The influence of long-term DGN stimulation on sexuality is not known.
Future development requires an electrode that fixates itself and does not dislocate and remains 
in the proper position where it is originally implanted. It is challenging to develop an electrode 
that stays in a stable position during normal activities as the pubic area consists meanly of 
fatty tissue. Another solution would be a self “thinking” electrode that after dislocation find its 
way back to its original implanted position. Concerning the internal pulse generator (IPG) an 
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important future development would be a fully implanted system consisting of an electrode 
and an IPG. The implant must be activated using a wireless device that is easy to control. Ideally, 
instead of manually turning or pushing a button while feeling urge, a sensor that continuously 
monitors bladder activity should be used to set off the conditional stimulation. In this way a 
closed loop system could be formed. There is ongoing research into bladder sensors, but until 
now no suitable device is available for clinical application. [31]
A last promising development is the implant for PTNS treatment. Original PTNS is an effective 
treatment, but time-consuming for both the patient and the caregiver. Various PTNS implants 
have been developed. The important advantage of performing tibial nerve stimulation (TNS) by 
an implant is the possibility to apply this treatment on demand at home, or any other preferred 
place, without the need to insert a needle. This is the first study of a novel implantable system 
for TNS. The results show that this new system is safe and the electrode is easy to implant. 
The short term clinical results show a significant decrease in 24-hour frequency, severe urinary 
urgency, severe incontinence episodes, in urinary loss per day and improvement in quality of 
life. In this study the implant was placed near the tibial nerve with an open surgical procedure 
under general anesthesia. A future development would be to develop an electrode that does 
not need to be located very close to the nerve to have the same stimulation effect. In that 
situation the implant could be placed by a percutaneous procedure under local anesthesia 
in an outpatient setting. In that way the implantation procedure will be easier, shorter and 
cheaper and still the electrical resistance of the skin will be bypassed. This would make it an 
ideal treatment modality.
Closing remark
Making a thesis is like travelling, you learn, you see, you experience, and you discover things. 
But one thing is for sure you find out you’re never finished, there is always more! 
During the development of this thesis in combination with clinical work I learnt a lot about 
OAB and its treatment options. But even more important I saw what a major impact OAB 
syndrome can have on patients lives and the desperation of some patients suffering it. This 
made me realize that research in this field is important. We need to develop new treatments 
or to improve existing therapies to increase the quality of life for patients suffering from OAB. 
To my opinion some good studies were done with clinical approaches to treat OAB, but we 
are not there yet. I hope that in the future we will cure OAB or at least rule out OAB as a 
bothersome syndrome and diminish it to a complex of symptoms without bother.
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De International Continence Society (ICS) heeft het overactieve blaas (OAB) syndroom 
gedefinieerd als urge voor urine, vaak samengaand met frequency en nocturia, met of 
zonder urge-incontinentie, in de afwezigheid van een urineweginfectie of andere duidelijke 
verklarende pathologie. 
Het OAB syndroom komt vaak voor en behandeling ervan kan een uitdaging zijn. OAB 
symptomen hebben een significant negatief effect op de kwaliteit van leven van patiënten 
die deze symptomen ervaren. Daarnaast brengt het hoge kosten met zich mee voor 
de samenleving. De afgelopen decennia zijn er verschillende behandelingen voor OAB 
ontwikkeld en onderzoek is nog volop gaande. Momenteel bestaat de behandeling van OAB 
uit: conservatieve therapieën, zoals het aanpassen van leefstijl en bekkenbodemfysiotherapie 
met of zonder biofeedback; medicamenteuze therapie, zoals anticholinergica en β-3 
agonist; minimaal invasieve chirurgische behandelingen, zoals neuromodulatie en botuline 
toxine A (BTA) behandeling; en in uiterste gevallen de grotere chirurgische behandelingen 
zoals blaasaugmentaties en urinedeviaties. Chirurgische behandelingen worden met name 
aangeboden aan patiënten bij wie conservatieve en medicamenteuze therapieën niet werken, 
of wanneer er te veel bijwerkingen optreden. 
Dit proefschrift gaat over OAB in de klinische praktijk, de prevalentie van OAB en bestaande/ 
experimentele minimaal invasieve chirurgische behandelingen voor OAB. De exacte 
prevalentie van OAB varieert met leeftijd en geslacht. Lower urinary tract symptoms (LUTS) 
is een verzameling van symptomen van de lagere urinewegen. Een gedeelte van deze 
symptomen vormen het OAB syndroom: urge, frequency, nocturia en urge-incontinentie. 
Kennis over de prevalentie van LUTS/OAB en de hinder die patiënten hiervan ondervinden, 
in verschillende leeftijdsgroepen en geslacht, is belangrijk om vast te stellen wat als “normaal” 
of fysiologisch verondersteld kan worden. Dit is met name belangrijk bij het behandelen van 
patiënten en het uitvoeren en interpreteren van wetenschappelijke studies. 
De prevalentie en ervaren hinder van LUTS/OAB symptomen bij jonge, anderszins gezonde 
vrouwen die nooit zwanger geweest zijn, is nog niet eerder uitgebreid bestudeerd. In 
hoofdstuk 2 wordt een studie hiernaar beschreven. In deze studie wordt een hoog percentage 
LUTS gevonden, maar met weinig ervaren hinder. De vrouwen scoorden hoog bij de vragen 
over hoe vaak ze een symptoom ervaarden “symptoomscore”, maar relatief laag bij de vraag 
hoeveel hinder ze van dit symptoom ondervonden “botherscores”. Door 94,3% van deze 
vrouwen werden LUTS gerapporteerd. De OAB symptomen urge en urge-incontinentie 
werden gezien bij 14,5% respectievelijk 3,8% van deze vrouwen. Van deze vrouwen had 
9,5% een dagfrequentie van meer dan 9 keer per dag en een nachtfrequentie van 1 keer 
per nacht werd bij 18,2% gezien. Bij alle LUTS werd een positieve correlatie gezien tussen 
de frequentie van het voorkomen van een symptoom en de ervaren hinder hiervan. Des te 
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vaker een symptoom bij iemand voorkwam, hoe meer hinder ervan ervaren werd. De hoogste 
“botherscores” werden gezien bij incontinentie en urge. Aangezien dit gezonde jonge 
vrouwen betrof, die niet de intentie hadden met deze symptomen naar een arts te gaan èn 
lage botherscores aangaven, moet afgevraagd worden of deze “LUTS” niet als fysiologisch 
beschouwd moet worden.
Wanneer er geen verbetering van de OAB symptomen optreedt met conservatieve en 
medicamenteuze therapieën worden tegenwoordig vaak BTA behandelingen toegepast. Het 
is een effectieve en relatief eenvoudige procedure voor de behandeling van OAB. BTA is in 
verschillende formules verkrijgbaar, zoals abobotulinum toxin A (DYSPORT) en onabotuline 
toxin A (BOTOX). BTA wordt middels een cystoscoop met een injectienaald in de blaas 
geïnjecteerd. Sinds het begin van de 21e eeuw wordt BTA gebruikt in wetenschappelijk 
verband of in een off-label setting voor de behandeling van OAB. In augustus 2011 heeft de 
U.S. Food and Drug Administration (FDA) BOTOX injecties in de blaas goedgekeurd voor de 
behandeling van urge-incontinentie bij patiënten met een neurologische aandoening die 
gepaard gaat met neurologische detrusoroveractiviteit. De FDA heeft de goedkeuring later 
uitgebreid voor het gebruik van BOTOX injecties in de blaas voor de behandeling van patiënten 
met idiopatische OAB die niet adequaat reageren op anticholinergica. BOTOX behandeling is 
een veelgebruikte relatief simpele behandeling. Er wordt veel wetenschappelijk onderzoek 
gedaan naar welke applicatie techniek de beste klinische resultaten geeft. Op dit moment 
is het niet duidelijk wat de kennis en behoefte naar training van urologen is over BOTOX 
behandelingen. Dit wordt bestudeerd in hoofdstuk 3. Na het vaststellen van de behoefte 
naar training van urologen middels een vragenlijst werd er een literatuurstudie verricht 
om deze te kunnen beantwoorden. Uit de vragenlijst kwam naar voren dat veel urologen 
BOTOX injecties gebruikten voor de behandeling van OAB en dat er een vraag is naar training 
in de technische aspecten van het gebruik van BOTOX om de beste klinische resultaten te 
verkrijgen. BOTOX kan geïnjecteerd worden in de detrusor, submucosaal, op verschillende 
injectielocaties in de blaas en met een verschillend aantal injecties. Het is echter nog niet 
duidelijk welke injectietechniek en welke locaties in de blaas de beste resultaten geven. Ook is 
het niet bewezen of hetzelfde aantal eenheden BOTOX verdeeld over 10 of meerdere injecties 
een beter resultaat geeft. Literatuur onderzoek laat wel zien dat, de vroegere theorie dat BTA 
injecties in het trigonum vesico-ureterale reflux konden veroorzaken, verworpen kan worden. 
Er is geen voorspellende waarde gevonden van het vooraf verrichten van een urodynamisch 
onderzoek om de klinische uitkomst te voorspellen. 
Het effect van een BOTOX behandeling houdt gemiddeld 6-10 maanden aan. Het herhalen 
van de behandeling kan overwogen worden als het effect afneemt, maar niet eerder dan 
12 weken na de voorgaande injecties. Het is bewezen dat herhaalde BTA injecties geen 
inflammatoire dan wel fibrotische reacties geven in de blaaswand. 
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Net als BTA wordt neuromodulatie middels elektrostimulatie vaak gebruikt als een behandeling 
voor refractaire OAB. Hoofdstuk 4 gaat over verschillende neuromodulatie behandelingen. In het 
eerste gedeelte wordt een overzicht gegeven van de verschillende neuromodulatie technieken: 
hoe de behandeling in zijn werk gaat, de resultaten en de kosten ervan. Percutane nervus tibialis 
stimulatie (PTNS), sacrale zenuw stimulatie (SNS) en de meer experimentele behandelingen 
zoals nervus pudendus stimulatie (PNS) en nervus dorsalis genitalis stimulatie (DGNS) worden 
behandeld. In het tweede gedeelte wordt de perifere neuromodulatie besproken, met name 
PTNS. Bij perifere neuromodulatie worden perifere zenuwen gestimuleerd die de lagere 
urinewegen beïnvloeden. Voorbeelden hiervan zijn de nervus tibialis posterior, de nervus 
pudendus en de nervus dorsalis genitalis. De origine van deze zenuwen bevindt zich in de 
lumbale, sacrale en coccygeale zenuwwortels die ontstaan uit L2 tot S4. Afferente en efferente 
zenuwvezels treden via deze zenuwwortels uit het ruggenmerg naar de periferie en gaan daar 
gecombineerd verder als perifere zenuwen. De nervus tibialis posterior ontstaat uit de nervus 
ischiadicus, welke weer ontstaat uit zenuwvezels van de zenuwwortels L4 tot S3. De nervus 
dorsalis genitalis ontstaat uit de nervus pudendus, welke weer ontstaat uit de zenuwvezels 
van de zenuwwortels S2 tot S4.
Om meer te weten te komen over de geschiedenis van PTNS moet ver teruggaan worden in 
de tijd. Het is een oude Chinese traditie om acupunctuur van het onderbeen te verrichten. 
Met deze techniek, die meer dan 5000 jaar geleden in China ontwikkeld werd, wordt getracht 
de “energetische harmonie” van het urogenitaal stelsel te herstellen. Men doet dit door het 
stimuleren van specifieke punten op het onderbeen. Wilhelmus ten Rhyne (1647-1700) was 
een Nederlandse arts, werkzaam bij de Nederlands Oost-Indische Compagnie in 1673, waar hij 
kennismaakte met deze traditionele oosterse geneeswijze. In 1683 publiceerde hij een boek 
getiteld: “Dissertatio de Arthritide: Mantissa Schematica: De Acupunctura: Et Orationes Tres”. 
Hij beschreef hierin de kunst van het inbrengen en het positioneren van naalden voor het 
behandelen van ziektebeelden, waaronder ook die van de lagere urinewegen. Hij noemde 
deze techniek “Acupunctura” en hiermee was dit de eerste gedetailleerde studie op dit gebied. 
In het derde gedeelte van dit hoofdstuk wordt SNS beschreven. Tegenwoordig wordt SNS 
uitgevoerd met een 2 fase techniek. Men maakt gebruik van een zichzelf fixerende lead die 
vier elektrodes bevat. Deze techniek werd als eerst beschreven door Spinelli et al in 2003. 
De allereerste SNS implantatie in een urologische patiënt werd echter in 1982 verricht door 
Tanagho and Schmidt aan de University of California in San Francisco. Later verkreeg Interstim in 
1994 een CE-markering in Europa voor de behandeling van chronische functiestoornissen van 
de lagere urinewegen. In 1997 verkreeg Interstim een FDA goedkeuring voor de behandeling 
van urge-incontinentie van urine, welke in 1999 uitgebreid werd voor de behandeling van 
symptomen van urge/frequency en niet obstructieve urineretentie.
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Dit proefschrift bevat ook enkele veelbelovende nieuwe ontwikkelingen op het gebied van 
neuromodulatie voor de behandeling van het OAB. Hoofdstuk 5 gaat over experimentele 
neuromodulatie. Het eerste gedeelte bevat een pilot studie naar patiënt gestuurde nervus 
dorsalis genitalis stimulatie (NDGS) voor de behandeling van urge-incontinentie. Deze studie, 
uitgevoerd bij niet neurogene patiënten met urge-incontinentie, laat zien dat patiënt gestuurde 
NDGS middels een percutaan geplaatste elektrode mogelijk is voor een langere periode in de 
thuissituatie. Patiënt gestuurde NDGS gaf een positief effect op de OAB symptomen. Alhoewel 
het plaatsen gemakkelijk is, is het moeilijker om de elektrode zo te fixeren dat hij voor langere 
tijd op de correcte positie blijft. Verbetering van de hardware, zoals een elektrode die zichzelf 
fixeert in het omliggende weefsel en een makkelijk te bedienen stimulator, zijn noodzakelijk 
om NDGS in de toekomst mogelijk te maken. 
Het tweede gedeelte van dit hoofdstuk bevat een studie naar een implantaat voor nervus tibialis 
posterior stimulatie (NTPS). Dit implantaat maakt het mogelijk voor de patiënt om NTPS toe te 
passen, wanneer de patiënt dit wil, op de locatie waar de patiënt dit wil, zonder dat het nodig 
is om een naald te plaatsen. Deze studie met NTPS middels een implantaat, laat minimaal 
dezelfde resultaten zien als de resultaten die beschreven zijn voor PTNS. 
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Abbreviations
BTA: Botulinum Toxin A
BOTOX: onabotulinum toxin A
CIC: clean intermittent catheterisation
DC: detrusor compliance
DCN: dorsal clitoral nerve 
DGN: dorsal genital nerve
DGNS: dorsal genital nerve stimulation
DO: detrusor overactivity
DPN: dorsal clitoral nerve
DYSPORT: abobotulinumtoxin A
EAS: external anal sphincter 
ECU: external control unit 
EMA: European Medicines Agency 
EUS: external urethral sphincter 
FDA: Food and Drug Administration
GRA: global response assessments 
ICIQ-FLUTS: International Consultation on Incontinence Modular Questionnaire for Female 
Lower Urinary Tract Symptoms
ICS: International Continence Society
IDC: involuntary detrusor contraction
iDO: idiopathic detrusor overactivity
iOAB: idiopathic OAB
IPG: internal pulse generator 
IPSS: International Prostate Symptom Score
IQR: interquartile ranges
LDP: Long-term depression
LL-SEP: long latency somatosensory evoked potentials 
LTP: . Long-term potentiation 
LUTS: Lower urinary tract symptoms
MS: multiple sclerosis
MMV: mean voided volume 
NDGS: nervus dorsalis genitalis stimulatie 
NDO: neurogenic detrusor overactivity
OAB: overactive bladder syndrome
PNE: percutaneous nerve evaluation 
PN: pudendal nerve
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PNS: pudendal nerve stimulation
PPBC: Perception of the Bladder condition
PPD: pads per day 
PPIUS: Patient Perception of Intensity of Urgency Scale
PTN: posterior tibial nerve
PTNS: percutaneous tibial nerve stimulation
PVR: post void residu
QoL: Quality of life
SD: standard deviation 
SCI: spinal cord injury
SDGNS: subject controlled, on-demand, dorsal genital nerve stimulation
SEP: Somatosensory evoked potentials
SL-LEP: Short Latency somatosensory evoked potentials 
SNS: sacral nerve stimulation
SODGNS: subject controlled, on demand, dorsal genital nerve stimulation
SSIE: Severity Score of Incontinence Episodes
TNS: Tibial nerve stimulation
UDI: urodynamic investigation
UI: urinary incontinence
UTI: urinary tract infection
UUI: urgency urinary incontinence
VUR: vesicoureteral reflux
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